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Abstract 
Lipid metabolic reprogramming is an established hallmark of cancer development, which 
among others includes a distinct fatty acid biosynthesis and metabolism due to the 
enhanced cellular growth and proliferation of cancer cells. Cell membranes are built by 
phospholipids, which are fatty acid-containing lipid species. Alterations to the fatty acid 
content may influence the membrane properties, such as fluidity, permeability and 
membrane lipid-related signaling, thus favoring tumor growth, progression and metastasis. 
The membrane remodeling is highly affected by the intracellular lipid pool, which in turn 
depends on both the endogenously produced fatty acids and their dietary intake. Key 
enzymes that are involved in lipid biosynthesis, show increased activity along tumor 
development and progression. Some chemotherapeutics have also been reported to 
influence the characteristics of the plasma membrane, while the final outcome of chemical 
exposure depends on membrane-related signaling (e.g. lipid rafts involving the death 
receptor pathway).  
The first part of the present thesis aimed at the in vitro evaluation of the effects of the 
compound [Cu(TPMA)(Phenanthroline)](ClO4)2, a novel copper complex, on the cell 
viability and membrane fatty-acid lipidome. The copper complex was studied in vitro as a 
free compound or under an encapsulated form within polymeric nanoparticles in the 
neuroblastoma derived cell line NB100 cell line and breast carcinoma cell line MCF7. Its 
cytotoxicity was determined and the cell death pathways were analyzed with parallel 
monitoring of caspase activation. The membrane fatty acid composition was examined in 
cells treated with the half maximal effective concentration (EC50) of copper complex. 
Inhibitors of apoptosis and necroptosis and scavengers of oxidative stress were tested to 
evaluate their protective effect against copper’s cytotoxicity and membrane lipidome 
alterations. The copper complex exerted oxidative stress-mediated cytotoxicity and 
induced apoptosis and necroptosis in both cell lines. Membrane remodeling took place 
upon treatment with the copper complex with a specific increase of saturated fatty acids 
(SFA) and a decrease of monounsaturated fatty acids (MUFA), but not polyunsaturated 
fatty acids (PUFA). Assessment of the stearoyl-CoA desaturase (SCD1) activity in the 
presence of copper complex using a cell-free assay showed no enzymatic inhibition of 
MUFA biosynthesis and therefore no metabolic involvement to the observed membrane 
remodeling. Cells pre-treatment with apoptosis inhibitor and ROS scavengers prevented 
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both the cytotoxicity and the changes on fatty acid composition, suggesting a correlation 
between membrane remodeling and the cytotoxic mechanism caused by the complex. 
Palmitic acid supplementation influenced the cell response to copper complex exposure by 
enhancing its cytotoxic effect. Finally, encapsulation of the complex in polymeric 
nanoparticles protected the cell viability and prevented any changes on membrane fatty 
acid composition.   
The second project undertaken within the frame of this thesis involved the monitoring of 
fatty acid composition of erythrocyte membrane at different stages of tumor occurrence 
and at early points of tumor occurrence after administration of iron nanoparticles (Fe-NPs) 
and bleomycin. The animal model studied consisted in the tumor-bearing SCID mice, 
xenografted with the human glioblastoma U87MG cell line, while non-xenografted SCID 
and healthy Swiss mice were used as controls. Late stage tumor-bearing mice were 
characterized by statistically significant increase of SFA, accompanied by a decrease in 
total PUFA, unsaturation and peroxidation indices. Fe-NPs caused a notable membrane 
remodeling in healthy Swiss mice, characterized by lower SFA and PUFA levels and higher 
MUFA content. Although both relative amounts of ω-6 and ω-3 PUFA families decreased, 
their ratio (ω-6/ω-3) appeared to be increasing in Fe-NPs treated Swiss mice, compared to 
the untreated group. Tumor-bearing mice did not show altered fatty acid profile under any 
treatment. Bleomycin did no exert any significant effect on erythrocyte membrane 
lipidomic profile of either the tumor-bearing mice or the healthy ones. However, co-
treatment of tumor diseased mice with Fe-NPs and bleomycin led to a decrease of the ω-
6/ω-3 ratio in erythrocyte membranes. Erythrocyte membrane fatty acid analysis may 
provide insights on the endogenous fatty acid metabolism through the relative proportion 
of SFA to MUFA, while the effect of high oxidative stress can be depicted through the 
PUFA consumption and the consequent membrane remodeling. Since the fatty acids are 
part of our dietary intakes, their balance can also impact the drug outcomes and tumor 
progression.  
In conclusion, we could demonstrate through these studies that fatty acid-based membrane 
lipidomics can be a valuable tool for evaluating the nutritional conditions and metabolic 
status of an organism. Indeed, by enabling the monitoring of selected fatty acid alterations, 
this method can contribute to the development of multi-targeted antitumoral approaches 
through customized cell membrane rearrangement. 
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1. Introduction  
 
1.1 Fatty acid-based membrane lipidomics 
 
1.1.1 Plasma membrane 
The cell membrane is crucial for the organization and function of every living cell. It 
constitutes the physical and semi-permeable barrier separating the intracellular from the 
extracellular environment, thus circumscribing the cellular content [1]. The plasma 
membrane is involved in every aspect of cellular fate, from cell division to programmed 
cell death [2-4]. Besides its structural role, it is involved in the regulation of transmembrane 
transport of small molecules either through passive or active mechanisms. Cell membrane 
also participates in various cellular processes such as cell adhesion, recognition and 
signaling [1, 5]. 
 
1.1.1.1 Structure 
The plasma membrane is a dynamic, complex structure of lipids and proteins in a fluid 
state, organized in the well-known mosaic model, according to which most of its molecules 
are able to move about in the plane of the membrane [6]. The most abundant membrane 
lipid species are the amphipathic glycerol-based phospholipids, which spontaneously form 
the lipid bilayer due to the hydrophobic effect [7]. Therefore, the major core of a biological 
membrane is self-organized, with the hydrophobic tails being eliminated from water and 
facing each other, while the polar headgroups form an ionic surface interacting with water 
(see Figure 1.1). Cholesterol is another major lipid component of the plasma membrane, 
which is embedded in the phospholipid bilayer and contributes to its fluidity [8]. 
Transmembrane or anchored integral proteins are also found in the membrane assembly 
and they are connected to phospholipids mainly by noncovalent interactions [9]. Membrane 
protein-lipid interaction has been recently reported to have a significant effect on the 
stabilization of membrane protein oligomers and on cell susceptibility to aberrant protein 
oligomers [10, 11]. Peripheral proteins are bound to the integral ones at specific binding 
sites [9]. Membrane protein molecules are mediating almost all membrane-related 
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functions, such as transport of specific molecules, detection and transduction of chemical 
signals [1, 12]. In addition, the plasma membranes may also contain glycolipids and 
glycoproteins, whose carbohydrates components play a significant role in cell-cell 
interaction processes [13, 14].   
 
Figure 1.1: Schematic diagram of the structure of a typical biological membrane. The phospholipid 
bilayer, the main matrix of all cellular membranes, is made of two phospholipid leaflets whose fatty 
acyl tails form the hydrophobic core of the bilayer; their polar, hydrophilic head groups face the 
aqueous cytoplasm and extracellular environment. Integral proteins are embedded in the bilayer 
and peripheral ones are mainly associated with the membrane by specific protein-protein 
interactions. Oligosaccharides bind to membrane proteins and lipids, forming glycoproteins and 
glycolipids, respectively (Lodish H et al., 2000, Molecular Cell Biology, New York: W. H. 
Freeman, 4th edition). 
 
As mentioned above, the fundamental matrix of the plasma membrane is the lipid bilayer, 
which is formed by phospholipids. Every phospholipid molecule is made of a hydrophilic 
head and a hydrophobic tail, as shown in Figure 1.2. The backbone of membrane lipids can 
be either the glycerol or the sphingosine, thus respectively forming the 
glycerophospholipids (GPLs) or the sphingophospholipids (SPLs). Within an individual 
glycerophospholipid, fatty acyl chains are attached to the C1 and C2 carbon atoms, while 
a phosphate group is attached to the C3 carbon atom of the glycerol molecule. Variable 
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polar groups are attached to the phosphate, such as choline, ethanolamine, serine, and 
inositol. Based on the type of polar head the major structural lipids in eukaryotic 
membranes are the phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylinositol (PI) and phosphatidic acid (PA) when no 
polar group is attached to the phosphate. Sphingomyelin (SM) consists of a phosphocholine 
polar group and it is among the few phospholipids that contain a sphingosine molecule as 
a backbone, in the amine group of which a fatty acid is attached. The relative distribution 
of the phospholipids varies within the different cell types and tissues. However, PC is the 
most abundant (>50%) phospholipid in eukaryotic membranes.  
 
 
Figure 1.2: Common structures of glycerophospholipids (GPLs) with a glycerol backbone and 
sphingomyelin as a representative of a sphingophospholipid (SPLs). Modified from Lordan R et 
al., 2017, Molecules, MDPI. 
 
The phospholipids are asymmetrically distributed between the two leaflets of the 
membrane bilayer. The outer layer contains mainly PC and SM, whereas the inner leaflet 
consists mainly of PE and PS. The asymmetric lipid distribution between the two leaflets 
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contributes to curvature stress in biological membranes, which is useful for the membrane 
budding, fission and fusion [15] as well as the conformation of membrane proteins and 
modulation of their function. Polar lipid heads are involved with strong electrostatic 
interactions and hydrogen bonds with amino acid residues the interface surface of the 
membrane proteins and the charge and aqueous their microenvironment can affect the 
activity of peripheral membranes proteins [15-17]. The hydrophobic domain is a 
diacylglycerol (DAG) made of long fatty acid chains that usually range from 14 to 24 
carbon atoms. The fatty acid tails can be either unsaturated (with one or more cis double 
bonds) or saturated (without any double bonds). Usually, within the hydrophobic domain, 
one chain is unsaturated and the second one saturated. Both the length and saturation degree 
of the fatty acid chains can influence the packing of the phospholipid molecules against 
one another, thus affecting the fluidity of the lipid bilayer. Considering the variety of 
phospholipids’ headgroups and their combination with several different fatty acids, the 
content of individual phospholipid species can be relatively diverse. This results in 
increasing membrane’s flexibility and may be needed for the numerous processes in which 
phospholipids have been reported to be involved [18].  
 
1.1.1.2 Physicochemical properties 
The plasma membrane is characterized by various physicochemical properties, such as the 
membrane thickness, lipid packing, fluidity, elasticity, permeability, flipflop, protein 
activity, fusion, blebbing and the structure and function of lateral and transmembrane 
domains. The kind of lipids building the biological membrane is a parameter that affecting 
most of these properties. However, it is reported that the physical properties of any lipid 
mixture are a collective property determined by the single lipid components [19]. The 
plasma membrane is constituted of a large variety of lipid molecules, each of them having 
different physical properties. As a result, every lipid moiety contributes collectively to the 
final properties of the membrane assembly. Several biophysical and biochemical studies 
on membrane lipids in parallel with genetic manipulation of membrane lipid composition 
have indicated that the Lα state of the membrane bilayer is required for cell viability and 
that cells adjust their lipid content in response to external factors in order that the collective 
property of the membrane exhibits the Lα state [19].  
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The physical and chemical properties of the membrane influence several cellular processes, 
thus suggesting that the lipids are not only structural components, but they also have a 
dynamic role in cell function [20, 21]. A key factor affecting the physicochemical 
properties of the membrane is the type of fatty acid moieties that are present to the 
phospholipid molecules [22]. The fluidity of the hydrophobic domains of the phospholipids 
is a function of the fatty acid chain structure and temperature [23], as depicted in Figure 
1.3. At a given temperature the fluidity of the hydrocarbon core of the membrane bilayer 
increases with higher content of unsaturated alkyl chain or with smaller alkyl chain length. 
Most phospholipid molecules have one cis-unsaturated fatty acyl chain, which enables 
them fluid at room temperature. Higher temperature leads to increased mobility of the fatty 
acid chains, which in turn increases the fluidity and the space occupied by the hydrophobic 
domain of lipids. 
 
 
Figure 1.3: The structure of fatty acid chain influences the membrane fluidity. Saturated fatty acids 
form a more rigid and less fluid lipid bilayer due to the tight packing of the straight chains. The 
double bonds of unsaturated fatty acids create a bend in the fatty acid tail, thus leading to increased 
membrane fluidity. Modified from Jich et al. (2010) [24]. 
 
1.1.2 Membrane fatty acids 
As mentioned above the major building block of membrane assembly is the phospholipid 
molecule whose hydrophobic tail contains usually two long fatty acid chains. The fatty 
acids (FA) are aliphatic chains with a carboxylic acid group (-COOH) at the end of the 
chain. Fatty acids naturally occurring in phospholipids commonly have a chain of 14 to 24 
carbons (usually unbranched and even-numbered), which may be saturated or unsaturated. 
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Odd-numbered fatty acids are most frequent in bacteria and lower plants or animals [25]. 
In eukaryotes, the fatty acid chains are esterified to the positions C1 and C2 of the L-
glycerol, as depicted in Figure 1.2. The acyl chain can vary in length and degree of 
unsaturation, thus affecting the properties of each moiety. 
 
1.1.2.1 Nomenclature 
For the precise description of a fatty acid molecule, the length of the alkyl chain, the number 
of double bonds and their exact position along the hydrocarbon chain must be defined. The 
exact annotation suggests the biological reactivity of each fatty acid moiety as well as of 
the lipid-containing the specific fatty acid molecule. There are several different naming 
systems used for the fatty acids [26, 27]. Amongst them are: 
Trivial nomenclature 
It involves the use of non-systematic historical names which are commonly used in 
literature. Most of the common FA have trivial names in addition to their systematic names. 
Trivial names do not contain any pattern or clue to the structure and they typically derive 
from a common source of the compound or the source from which it was originally isolated.  
Systematic nomenclature 
The systematic (or IUPAC) names follow the nomenclature rules of the International Union 
of Pure and Applied Chemistry. In the IUPAC system, carbon atoms numbering starts from 
the carboxylic acid end and the rest positions in the chain are denoted with reference to it. 
Double bonds are labelled with cis-/trans- or E-/Z- notation, respectively. These names 
describe the structures in detail and give a clear description of the FA chains. The 
systematic name used for a fatty acid is derived from the name of its parent aliphatic chain 
by substituting the suffix -e with -oic. For example, the C18 saturated fatty acid is called 
octadecanoic acid since its parent hydrocarbon is the octadecane. The C18 fatty acids that 
have one, two and three double bonds are named octadecenoic, octadecadienoic and 
octadecatrienoic acid, respectively. In the case of ionized or esterified fatty acids, it is more 
suitable to name them according to their carboxylate form: for instance, stearate or 
octadecanoate, instead of stearic or octadecanoic. 
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Shorthand nomenclature 
This is another systematic way of naming the fatty acids. It is a carboxyl-reference system 
that indicates the number of carbons, the number of double bonds and the positions of the 
double bonds, counting from the carboxyl carbon (which is numbered 1, as in the IUPAC 
system). Lipid names take the form C:D, where C is the number of carbon atoms and D is 
the number of double bonds in the FA. For example, the notation 18:0 denotes a C18 fatty 
acid with no double bonds, whereas 18:2 signifies that there are two double bonds. This 
notation is sometimes puzzling since different FA can have the same shorthand 
nomenclature, like positional or geometrical isomers. Consequently, it is usually paired 
with an ∆x term, where x is a number representing the position of the double bond (xth 
carbon-carbon bond), counting from the carboxylic acid end. Each double bond is preceded 
by a cis-/trans- notation, indicating the configuration of the molecule around this bond. For 
instance, cis-Δ9 stands for a cis double bond between the carbon atoms 9 and 10; trans-Δ5 
stands for a trans double bond between carbon atoms 5 and 6. 
omega-reference system 
The omega-x (ω−x or n-x) nomenclature does not provide names for individual 
compounds. It is applied when double bonds are present and indicates the position of the 
double bond closest to the omega carbon, which is numbered 1 in this case. According to 
the "omega nomenclature", as omega carbon is designated the terminal methyl carbon. This 
system is useful for the categorization of FA by their physiological properties since there 
are significant differences between omega-3 and omega-6 counterparts. For example, 
linoleic acid is classified as a ω−6 or omega-6 FA, and so it shares some properties with 
other members of the ω-6 family. The omega position of the first double bond is also 
helpful to avoid confusion in case of positional isomers (fatty acids differing just in the 
position of double bonds). Sometimes, the shorthand nomenclature contains the positioning 
of the first double bond from the omega end written in parenthesis, instead of the ∆x term.  
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Table 1.1: List of main fatty acids naturally present in eukaryotic membranes, described by their 
shorthand, trivial and systematic nomenclature and their omega annotation. The melting point for 
each FA is also reported (values retrieved from https://pubchem.ncbi.nlm.nih.gov); na: not 
available. 
C:D 
Trivial name 
(x-acid) 
IUPAC name 
(x-acid) 
ω-n 
Melting 
point (°) 
Saturated Fatty Acids 
14:0 Myristic Tetradecanoic / 53.9 
16:0 Palmitic Hexadecanoic / 61.8 - 63 
18:0 Stearic Octadecanoic / 68.8 - 72 
20:0 Arachidic Eicosanoic / 75.4 
Monounsaturated Fatty Acids 
16:1 Sapienic 6Z-hexadecenoic ω-10 na 
16:1 Palmitoleic 9Z-hexadecenoic ω-7 -0.1 
18:1 Oleic 9Z-octadecenoic ω-9 13.4 – 16.3 
18:1 Vaccenic 11Z-octadecenoic ω-7 39 
20:1 Gondoic 11Z-eicosenoic ω-9 na 
Polyunsaturated Fatty Acids 
18:2 Linoleic 9Z,12Z-octadecadienoic ω-6 -8.5 
18:3 α-Linolenic 9Z,12Z,15Z-octadecatrienoic ω-3 -16.5 
18:3 γ-Linolenic 6Ζ,9Ζ,12Ζ-octadecatrienoic ω-6 -11 
20:3 Dihomo-γ-linolenic 8Z,11Z,14Z-eicosatrienoic ω-6 na 
20:4 Arachidonic 5Z,8Z,11Z,14Z-eicosatetraenoic ω-6 -49 
20:5 EPA 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ω-3 -54 
22:5 DPA 7Z,10Z,13Z,16Z,19Z-docosapentaenoic ω-3 na 
22:6 DHA 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ω-3 -44 
 
 
1.1.2.2 Classification 
In general, fatty acids can be divided according to a) the chain length into short (C2-8), 
medium (C8-10) and long (>C12), b) the degree of saturation into saturated and 
unsaturated, c) the biological value into essential and non-essential and d) the chain 
structure into aliphatic, branched and cyclic. Membrane fatty acids, which consist the 
hydrophobic domain of phospholipids, contain long aliphatic alkyl chains, with an even 
number of carbon atoms, typically atom ranging between 14 and 24. For this reason, further 
description of fatty acid classification in this chapter will concern only their saturation 
degree and their biological significance. 
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The hydrocarbon chain of membrane fatty acids can vary in the number of double bonds 
and thus be classified into saturated or unsaturated. The differences between saturated and 
unsaturated fatty acids, as well as the variation in geometry of unsaturated FA, determine 
the properties of membrane structure, thus influencing its microdomain organization and 
altering numerous cellular processes [21, 28]. 
Saturated fatty acids 
Saturated fatty acids (SFA) do not contain any double bond along the alkyl chain. The term 
‘saturated’ is used because all the carbon atoms contain as many hydrogen atoms as 
possible. The general formula of SFA is CH3(CH2)nCOOH. The lack of any double bonds 
or other functional groups enable these fatty acids to be nearly chemically inert and thus 
subject to drastic chemical conditions, such as temperature and oxidation. In Figure 1.3, 
the structures of two representative members of the SFA family are depicted. 
 
 
Figure 1.3: Molecular structure of representative members of saturated fatty acids (SFA) family. 
Palmitic (16:0) and stearic (18:0) acid are characterized by straight chains that differ in length by 
two carbon atoms. 
 
 Palmitic (16:0) and stearic (18:0) acid are the two most commonly occurring SFA. As 
shown in Table 1.1, the long SFA are characterized by high melting points, which means 
that they are in the solid state at room temperature. This physicochemical behavior is a 
consequence of their molecular structure (straight shape chains) that contributes to the high 
packing of SFA in phospholipid bilayer. 
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Unsaturated fatty acids 
The hydrocarbon chain of unsaturated fatty acids (UFA) may contain one or more double 
bonds. Unsaturated fatty acids exhibit the positional and geometrical isomerism at the 
double bonds, which are characterized by cis-configuration in the majority of naturally 
occurring UFA. According to the number of double bonds, the unsaturated fatty acids can 
be further divided into mono- and polyunsaturated FA. 
• Monounsaturated Fatty acids (MUFA) 
Monounsaturated FA contain only one double bond along the alkyl chain. The 
general formula of MUFA is CH3(CH2)xCH=CH(CH2)yCOOH. The position of the 
unique double bond can vary a lot. The presence of the double bond increases the 
FA fluidity since a double bond in the cis configuration provokes a bend in the alkyl 
chain, as shown in Figure 1.4. This bending leads to a total spatial width of 0.72 nm 
for a cis-MUFA compared to the 0.32 nm one that characterizes the saturated 
structures. 
 
 
Figure 1.4: Molecular structure of representative members of monounsaturated fatty acids 
(MUFA) family. The formation of a double bond in Δ9 position creates a bend to the chain 
of palmitoleic (16:1-c9) and oleic (18:1-c9) acid. 
 
Unlike the SFA that have the tendency to pack in a membrane structure, MUFA 
cause a higher molecular disorder due to their three dimensional shape. As a 
consequence, their presence in membrane assembly influences its fluidity and 
permeability [28]. MUFA have a lower melting temperature than SFA and they are 
in liquid state at normal temperature and semisolid or solid when refrigerated. 
Amongst the most common MUFA members are the palmitoleic acid (16:1,cis-∆9), 
oleic acid (18:1,cis-∆9) and vaccenic acid (18:1,cis-∆11). 
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• Polyunsaturated Fatty acids (PUFA) 
Polyunsaturated FA contain two or more cis double bonds, which are usually 
separated from each other by a single methylene group (methylene-interrupted 
unsaturation) and have the general formula -C-C=C-C-C=C-. PUFA, as unsaturated 
fatty acids, have a more extended shape than SFA due to the presence of double 
bonds that increase the bending of the hydrocarbon chains. Therefore, PUFA have 
significantly lower melting points compared to other FA families, as presented in 
Table 1.1. PUFAs are important structural components and contribute to membrane 
fluidity and selective permeability [29]. The higher the degree of unsaturation in 
FA (more double bonds), the more susceptible they are to lipid peroxidation, 
whereas UFA can be protected from lipid peroxidation by antioxidants [30, 31]. 
Polyunsaturated fatty acids are usually divided into omega-6 (ω-6) and omega-3 
(ω-3) series, based on the distance between the final methyl group and the closest 
double bond in the chain. Thus, starting the numbering from the omega carbon, the 
first double bond is at the position C6 and C3 for the ω6 and ω3 family, respectively. 
Figure 1.5 shows the molecular structure of representative members of each PUFA 
family.  
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Figure 1.5: Molecular structure of representative members of polyunsaturated fatty acids 
(PUFA) family. PUFA have an extended shape due to the multiple double bonds and are 
generally divided into omega-6 and omega-3, based on the distance between the final 
methyl group and the closest double bond in the chain. 
 
Geometrical isomerization 
The double bond in unsaturated fatty acids can be either in cis or trans configuration (Z- or 
E-, respectively, according to IUPAC notation). In the cis configuration the two alkyl 
groups (R1 and R2) are on the same side of the double bond, where in trans geometry they 
are on the opposite sides (Figure 1.6). In eukaryotes, the double bond of unsaturated fatty 
acids has prevalently cis geometry. During fatty acid biosynthesis, the insertion of cis 
double bonds is catalyzed by desaturases, which act in a regioselective and stereospecific 
way [32]. The trans geometry is not naturally present since these eukaryotic enzymes are 
not capable to form trans double bonds or catalyze their cis-trans isomerization. The loss 
of the natural cis geometry changes dramatically the molecular shape of the fatty acid chain, 
thus affecting several membrane properties, such as the diameter, fluidity and permeability 
[33, 34]. For instance, elaidic acid (9trans-18:1), which is the geometrical isomer of oleic 
acid (9cis-18:1), is characterized by linear alkyl chain instead of the typical bending 
structure of MUFA, as shown in Figure 1.6.  
 
 
Figure 1.6: Example of geometrical cis-trans isomerization in fatty acids. The configuration of the 
double bond influences the shape of the alkyl chain; cis geometry produces a kink in the molecule, 
while trans geometry favors a linear carbon chain. 
 
Trans fatty acids (TFA) usually originate from processed food products (deodorized or 
partially hydrogenated) [35, 36]. Another dietary source of TFA is the consumption of dairy 
products and meat due to the microbial biohydrogenation that takes place in the stomach 
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of ruminants [37]. Contrary to eukaryotes, some Gram-negative bacteria have the ability of 
endogenous  cis–trans isomerization  as a response to environmental stress conditions [38]. 
In eukaryotic cells, the conversion of the natural cis fatty acids to their trans isomers may 
occur endogenously under stress condition and involves a thiyl radical catalytic mechanism 
[39-41]. 
 
1.1.2.3 Biosynthetic vs essential fatty acids 
Mammals can synthesize saturated and monounsaturated fatty acids, but they are unable to 
synthesize FA containing more than one double bond (PUFA). Indeed, they lack the 
enzyme system that is responsible for the introduction of a double bond in a 
monounsaturated alkyl chain. Consequently, the fatty acids not being synthesized by the 
organism should be supplied through diet and are known as essential or semi-essential FA.  
 
De novo biosynthesis 
In adult humans, the de novo synthesis of fatty acids is taking place mainly in the liver, 
adipose tissue and lactating breast [42]. The fatty acids that contain up to 16 carbon atoms 
are synthesized by the fatty acid synthase (FAS). FAS is a cytoplasmic enzyme that is 
composed of two similar subunits (~250 kDa each) and acts as a multifunctional complex. 
It is characterized by seven different enzymatic activities within two catalytic centers. Fatty 
acid synthesis by FAS is initiated by the condensation of an acetyl-CoA and malonyl-CoA 
molecule, while NADPH serves as the reductant in this process. The addition of a two 
carbon-unit from malonyl-CoA is repeated seven times in a cyclic manner, thus leading 
eventually to the production of the saturated C16 fatty acid (palmitic acid) [43-45]. Due to 
the mechanism of their de novo biosynthesis, most of the natural FA have an even number 
of carbon atoms. The palmitic acid is the starting point for the biosynthesis of other fatty 
acids, which is catalyzed by a set of microsomal enzymes generating modified alkyl chains; 
elongated or desaturated ones (see Figure 1.7). The fatty acids produced by FAS, as well 
as those originated from the diet, can be further elongated into very-long chain fatty acids 
(VLCFA) containing more than 18 carbon atoms. The overall elongation reaction takes 
place mainly in the endoplasmic reticulum (ER) by four membrane-bound enzymes. The 
enzymatic steps involved in this process are similar to the synthesis of palmitate since 
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malonyl‐CoA and NADPH are respectively used as an intermediate and reductant. The 
proteins performing the successive steps of VLCFA extension are individual molecules, 
which could be physically associated, contrary to the FAS multi-enzyme complex [46, 47]. 
Three of the four enzymatic activities in VLCFA elongation are localized to the 
cytoplasmic side of ER membranes, while the enzyme performing the third step is 
suggested to be embedded in the membrane [48].  In humans, seven enzymes (ELOVL 1–
7) have been identified with the ability to elongate the >16C fatty acid chains into VLCFA 
[49]. Despite the capability of all the seven elongation enzymes to catalyze the 
condensation reaction in the elongation cycle, they are characterized by differential 
substrate specificity and tissue distribution [50]. In addition, palmitate and other long FA 
can be further processed by acyl-CoA desaturases that can modify the structure and 
properties of long-chain fatty acids by introducing a double bond at a specific position on 
the acyl chain [51]. An ER-bound enzymatic complex including NADH-cytochrome b5 
reductase, cytochrome b5 and a desaturase catalyzes the desaturation. These enzymes use 
molecular oxygen, as an electron acceptor, while in this case the NADH is the reducing 
agent. [52-54]. Mammalian cells express three different desaturases that are generally 
divided into two distinct families: stearoyl-CoA desaturases (SCDs) [55] and fatty acid 
desaturases (FADS) [56]. Human desaturases catalyze the introduction of a double bond at 
specific positions (Δ9, Δ6 and Δ5) into the saturated fatty acyl-CoA chain. SCDs, also 
known as Δ9 desaturases, catalyze the insertion of a single double bond at the carbon C9 
(counting from the carboxylic acid group). The oleic and palmitoleic acids are the main 
products of SCDs synthesized by the desaturation of the SFA stearic and palmitic, 
respectively. In humans, two SCD isoforms (SCD1 and SCD5) have been identified, with 
the SCD1 being the most commonly expressed among tissues [57]. FADS1 and FADS2, 
which respectively have Δ5- and Δ6-desaturase activities are mainly involved in the PUFA 
biosynthetic pathways, as described later in this paragraph. However, FADS2 can 
potentially also act on palmitic forming the sapienic acid (cis-6 hexadecenoic), which is 
reported to be the most abundant fatty acid in human sebum [58]. The formed MUFA may 
undergo further elongation by the previously-mentioned elongation system. For example, 
palmitoleic (C16-Δ9) can be converted to the cis-vaccenic (C18-Δ11) and oleic (C18-Δ9) 
to gondoic acid (C20-Δ11). Consequently, this chain extension ‘shifts’ the position of the 
double bond by two carbon atoms, since the elongation occurs in the carboxyl terminus. 
Finally, it is worth mentioning that the intracellular fatty acid pool is enriched not only by 
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the endogenously synthetized FA but also by those obtained through the dietary habits of 
each individual.  
 
 
Figure 1.7: The biosynthesis pathways of SFA and MUFA family. Palmitic acid is synthesized by 
recurring reactions catalyzed by the enzymatic complex FAS. Elongases (elo) or desaturases 
(des6/9) can further modify the alkyl chain of palmitic acid and its downstream products.  SFA: 
saturated fatty acids; MUFA: monounsaturated fatty acids; FAS: fatty acid synthase. 
 
Essential fatty acids 
Despite their ability to synthesize saturated and monounsaturated fatty acids, animals are 
not capable to produce de novo polyunsaturated FA because they lack the required enzyme 
system that further desaturases oleic acid (18:1-Δ9) into linoleic acid (LA, 18:2-ω6) and α-
linolenic acid (ALA, 18:3-ω3) [59]. Therefore, these two PUFA moieties are considered as 
dietary essential fatty acids as they cannot be endogenously synthesized. However, they 
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themselves or their metabolic derivatives play an important role in human health and 
development by being involved in numerous biological functions [60, 61]. For instance, 
arachidonic acid (20:4-ω6), a metabolic derivative of linoleic acid, is the precursor 
molecule for the synthesis of prostaglandins by the cyclooxygenase enzyme system and 
leukotrienes by the lipoxygenase pathway in leucocytes [62]. The other members of PUFA 
family can be provided either through the dietary intake or synthesized from the 
nutritionally essential fatty acids (LA and ALA). LA and ALA are the starting points of 
PUFA biosynthesis in humans and can be further modified by the activity of desaturases 
and elongases, as depicted in Figure 1.8 [63]. As previously mentioned, PUFA can be 
divided into the omega-6 and omega-3 families, based on the position of the double bond 
closest to the methyl end of the alkyl chain. The precursors of these families (LA for ω-6 
and ALA for ω-3) can be transformed to more highly unsaturated FA by a series of common 
elongation and desaturation reactions in ER [64]. FADS1, FADS2 are the key desaturases 
in PUFA biosynthesis. For example, arachidonic acid (ARA), a long-chain ω-6 PUFA, is 
synthesized from LA, through the following successive reaction steps: the addition of a 
double bond by Δ6-desaturase to form γ-linolenic acid (GLA, 18:3-ω6), the elongation of 
GLA to form dihomo-γ-linolenic acid (DGLA, 20:3-ω6) and finally the addition of another 
double bond by Δ5-desaturase to form eicosatetraenoic acid (ARA, 20:4-ω6) [65]. Similar 
desaturation and elongation steps are utilized for the formation of eicosapentaenoic acid 
(EPA, 20:5-ω3), a member of omega-3 family. In higher eukaryotes for the synthesis of 
DHA, a downstream derivative of EPA, the latter is elongated to DPA-ω3 which is further 
elongated into tetracosapentaenoic acid (TPA, C24:5-ω3) and then TPA is desaturated to 
form ω3-tetracosahexaenoic acid (THA, C24:6-ω3) by a Δ6-desaturase. Finally, the THA 
undergoes beta-oxidation in peroxisomes to form the DHA-ω3 [66, 67]. On the contrary, 
lower eukaryotes are able to elongate the EPA-ω3 into DPA-ω3 and then desaturate the 
latter into DHA-ω3 by the Δ4-desaturase, an enzyme that is not present in mammals [68]. 
PUFA family members, such as ARA and DHA are considered as semi-essential fatty 
acids, since they can be synthesized endogenously by their precursors (LA or ALA). Semi-
essential FA turn into essential ones in case their precursors are missing from the diet. 
Interestingly, in vitro studies in glioma cells have shown that the occurrence of double 
bonds with trans configuration in PUFA influences the metabolic fate of the latter by 
affecting the processes of desaturation and elongation in the fatty acid chain [69, 70]. 
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Figure 1.8: PUFA biosynthesis in mammals. Linoleic (LA) and α-linolenic (ALA) acids are 
respectively the precursors of omega-6 and omega-3 family. LA and ALA are further converted to 
long chain fatty acids using a series of desaturation and elongation reactions in the endoplasmic 
reticulum. The final products of omega-6 and omega-3 biosynthetic pathways, DPA-ω6 and DHA-
ω3, respectively, are formed by β-oxidation in peroxisomes. Modified from Lauritzen et al. (2001) 
[71]. elo: elongase, des5/6: Δ5-/6-desaturase. 
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1.1.3 Membrane role in cell proliferation and survival related signaling 
 
Membrane lipids can affect both the 3D structure and the function of membrane-associated 
protein molecules through the protein-lipid interactions and the lipids’ self-association 
properties. The chemical and structural characteristics of phospholipids, such as the type 
of polar head, the alkyl chain length and unsaturation degree, can influence the specific 
protein-lipid interactions. Moreover, the lipids organization within the membrane assembly 
plays an important role regarding several of its properties, such as its fluidity, thickness 
and packing, also affecting the function of membrane proteins [19]. 
Besides serving as the building blocks of cellular membranes, fatty acids also contribute to 
the modulation of intracellular signaling pathways related to cell proliferation and survival 
[72]. Diverse external stimuli can induce the hydrolysis of sphingolipids or 
glycerophospholipids and lead to the formation of biologically active lipids, which can 
function as second messengers in the regulation of cell viability, mobility and inflammation 
[73]. Such examples of messenger lipids are the sphingosine 1-phosphate (S1P), lyso-
phosphatidic acid (LPA), inositol-trisphosphate (IP3) and DAGs, amongst others [74, 75]. 
The lipid signaling molecules can either get easily released from the membrane and act 
through membrane-related receptors [76], or can remain in the membrane and recruit 
cytosolic proteins [77]. LPA can also be formed extracellularly by the secreted 
phospholipase A2 (PLA2) or the lysophospholipase autotaxin (ATX), thus exerting both 
autocrine and paracrine signals [73, 78]. Since the membrane remodeling process, known 
as Lands’ cycle [79] takes place constantly, the composition of the intracellular lipid pool 
influences the phospholipids turnover and their fatty acid content. LPA contains one acyl 
chain that can belong to any family SFA, MUFA or PUFA, with the palmitoyl group (16:0-
LPA) being the most prevalent [78]. However, the acyl chain’s length and the unsaturation 
degree have been reported to affect the affinity of LPA receptor and its ligand [80], while 
only unsaturated FA containing-LPA was able to induce chemotaxis of immature dendritic 
cells [81]. 
The biological properties of the individual FA moieties also play significant role in the fatty 
acylation of proteins, such as the N‐myristoylation and S‐palmitoylation.  Fatty acylation 
is a post-translational modification regulating protein function (protein-protein and protein-
lipid interactions) as well as its intracellular trafficking and localization [82]. A profound 
example is the WNT proteins, which participate in the development and tissue homeostasis 
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related signaling [83]. The optimal function of WNT proteins requires their post-
translational S-palmitoleoylation by the membrane-bound O-acyltransferase porcupine 
[84]. Interestingly, β-catenin, a downstream transcriptional factor of Wnt pathway, is 
protected from proteasomal degradation by unsaturated fatty acids [85]. 
PUFAs also serve as precursors for the eicosanoid synthesis [62]. Eicosanoids are lipid 
mediators that regulate a wide range of physiological processes [86, 87] and therefore have 
profound effects on various pathological conditions [88]. In particular, ARA and EPA are 
released from cell membrane by phospholipases (mainly cPLA2) and then serve as the 
substrates of cyclooxygenase 1 (COX1) and lipoxygenase1 (LOX1). COX and LOX 
enzymes are responsible for the synthesis of prostaglandins and leukotrienes, respectively 
[89]. Eicosanoids usually interact with plasma or nuclear membrane receptors and are key 
effector molecules in inflammation, autoimmunity and cancer [89, 90]. Furthermore, the 
release of ω-6 PUFA from membrane favors the activation of signaling pathways related 
to cell proliferation and apoptosis [91, 92]. 
Finally, cardiolipin is a dimeric phospholipid in the inner mitochondrial membrane that 
undergoes continuous remodeling. Its participation in signaling platforms during the 
induction of apoptosis has been indicated by influencing the activity of the pro-apoptotic 
Bcl-2 proteins as well as the autoprocessing of caspase-8 [93]. Cardiolipin’s acyl chain 
composition is known to affect several aspects of mitochondrial function. In particular, the 
binding of cytochrome c in the inner mitochondrial membrane is influenced by the 
characteristics (length and saturation level) and oxidative state of cardiolipin’s acyl chains 
[94].  
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Figure 1.9: Examples of fatty acids’ multifaceted contribution to intracellular signaling processes 
and regulation of apoptosis; (a) Mitochondrial membrane composition affects the sensitivity to 
apoptotic signals; (b) Acylation of WNT protein triggers its secretion and thus activates the 
WNT˗β-catenin pathway; (c) Extracellular phospholipase autotaxin (ATX) releases 
lysophosphatidic acid (LPA) facilitating the autocrine signalling through LPA receptors (LPARs). 
Activation of the AKT signaling through the production of the second messengers PIP3 
(phosphatidylinositol-3,4,5-trisphosphate); (d) Arachidonic acid serves as the substrate for 
prostaglandin E2 production leading to the regulation of inflammation and immune response. 
Modified from Röhrig F. et al. (2016) [72] 
 
 
1.2 Membrane lipidome in cancer  
Metabolic reprogramming is an established hallmark of cancer that facilitates tumor growth 
[95, 96]. The deregulation of cellular metabolism and the acquisition of new metabolic 
features enable the cancer cells to sustain the continuous cellular growth and proliferation 
and effectively support their dissemination [97]. Cancer metabolic modifications include 
altered glucose metabolism, enhanced pentose phosphate pathway, elevated amino acid and 
lipid metabolism, increased mitochondrial biogenesis and macromolecules biosynthesis, 
amongst others [98-100]. Cancer cells are characterized by increased lipid metabolism due 
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to their elevated proliferation rate [101]. Lipids are the major building blocks of membrane 
and play an important role in energy storage and cell signaling. Consequently, the actively 
proliferating tumor tissues require higher amounts of lipids to satisfy their structural and 
functional needs [102, 103]. 
 
1.2.1 Altered fatty acid synthesis in cancer 
Cancer development is characterized by a distinct lipid metabolism as well as a fatty acid 
one [95, 103]. It is well known that the transformation of membrane lipid composition 
affects its fluidity, permeability as well as membrane lipid-related signaling, and can give 
favorable signals for tumor growth, progression and metastasis [72, 96, 97]. Membrane 
remodeling is affected by the intracellular lipid pool, which depends on both the 
endogenous fatty acid biosynthesis and the dietary intake, especially for the essential 
polyunsaturated fatty acid (PUFA) supply. Thus, membrane fatty acid composition is 
influenced by a combination of stabilized nutritional conditions and metabolic status [104]. 
Tumor initiation and propagation are characterized by an altered activity of enzymes 
involved in lipid biosynthesis, such as fatty acid synthase (FASN) and desaturases (SCD1, 
FADS1, FADS2). Indeed, together with the corresponding fatty acids, the increased 
enzymatic activities are pointed as significant markers of tumor presence and growth [42, 
72, 105, 106]. 
Fatty acid synthase (FASN) is the major lipogenic enzyme in humans since it is responsible 
for the de novo fatty acid synthesis. The upregulation of the endogenous fatty acid 
production has been reported by numerous studies [102, 103]. More particularly, 
overexpression and enhanced activity of FASN has been detected in various types of 
cancer, such as breast, ovarian, colorectal and prostate [42, 107, 108] [109-114]. 
Furthermore, elevated levels of FASN expression have been associated with poor prognosis 
and tumor aggressiveness [115-118]. Some studies support the hypothesis that the 
overexpression of Fasn gene may lead to neoplastic or malignant cell transformation by 
enhancing the lipogenesis along with increased cell growth and proliferation [119]. The 
expression of FASN is also elevated in proliferating fetal cells, thus suggesting that 
stimulated FASN activity might correspond to a less differentiated cell phenotype in tumor. 
[120]. Moreover, interaction between fatty acid synthase and human epidermal growth 
receptor 2 (HER2) in osteosarcoma cells has been reported [121]. FASN inhibition induces 
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programmed cell death in both in vitro and in vivo cancer models and suppresses the 
overexpression of the HER2/neu (erbB-2) oncogene and tyrosine-kinase activity in breast 
and ovarian cancer [122, 123]. FASN activity leads to the synthesis of the palmitic acid 
which besides its role in energy metabolism exerts pleiotropic effects on cellular function, 
as summarized in Figure 1.9 [42]. 
 
 
Figure 1.9: FASN-catalyzed synthesis of palmitic acid plays an important role in tumorigenesis. 
Palmitate is either incorporated in more complex lipid structures or conjugated to proteins. Its 
presence regulates the proper localization and function of several receptors that are involved in 
oncogenic signaling platforms. Modified from Jones et al. (2015) [124]. 
 
Palmitate can be incorporated to more complex lipids, such phospholipids, thus facilitating 
the membrane synthesis and cellular growth. In addition, it can be conjugated to proteins 
leading to their post-translational acylation, which in turn determines protein’s localization 
and function [84, 125]. Correlation between palmitic acid occurrence and the proper 
function of important oncogenic signaling platforms, like the PI3K/AKT/mTOR pathway,  
has also been reported [124]. 
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The significance of stearoyl-CoA (SCD1) in tumor development has also been thoroughly 
studied, since accumulation of monounsaturated fatty acids (MUFA) is a main feature in 
metabolic deregulation [126-129]. Being a key enzyme in lipogenesis regulation and 
responsible for MUFA synthesis, SCD1 activity supports the rapid cell growth and 
proliferation in cancer [42]. Furthermore, it contributes to the evasion of apoptosis, as well 
as to the tumor cell initiation and transformation, since it is involved in intracellular 
signaling, such as the PI3K-Akt and AMPK pathway [128, 130, 131]. Several studies have 
reported elevated expression levels of SCD1 desaturase in diverse types of cancer, such as 
breast, lung and prostate [132-136]. Inhibition of SCD1 activity not only reduces lipid 
biosynthesis, but also blocks cell cycle progression and induces cell apoptosis [137, 138]. 
On the contrary, dietary supplementation with oleic or palmitoleic, which are the metabolic 
products of SCD1, reversed cell proliferation blockage and restored intracellular lipids 
[137]. Examination of the mechanisms accompanying SCD1-mediated cancer progression 
by Chen et al. revealed a crosstalk between upregulated ceramide biosynthesis and SCD1 
inhibition in in vivo models of colorectal cancer [126]. Aiming at revealing the mechanisms 
underlying the cancer stemness, Noto et al. proved that SCD1 interacts with the Hippo 
signaling pathway. In particularly, it regulates the activity of YAP and TAZ through the 
Wnt/β-catenin pathway, thus contributing to the propagation of lung cancer stem cells 
[127]. Spheroids formed in primary cell cultures derived from lung adenocarcinoma 
patients express higher levels of SCD1 in comparison to the adherent cells [128]. In line 
with these findings, higher levels of unsaturated lipids were detected in ovarian cancer stem 
cells compared to non-stem cancer cells and were positively correlated with in vitro sphere 
formation efficacy and in vivo tumor initiation [128, 139]. Desaturases expression is 
controlled by the nuclear factor kappaB (NF-kB) and in turn their activity affects the NF-
kB pathway [139]. Moreover, Zhang et al. showed that the epidermal growth factor 
receptor (EGFR) binds and phosphorylates the SCD1 at Y55. This EGFR kinase activity is 
proved to be important for SCD1’s protein stability, intracellular MUFA levels and lung 
cancer growth [129]. The same group also proved a positive correlation between EGFR 
activation, SCD1 protein expression, SCD1 Y55 phosphorylation and poor patient 
prognosis in patients with non-small cell lung cancer [129]. High levels of SCD1 
expression have also been correlated with low overall survival in breast cancer and 
hepatocellular carcinoma patients [140, 141]. Overall, stearoyl-CoA desaturase-1 has been 
characterized as a central regulator in the orchestration of the complex metabolic and 
signaling events that govern cancer cells [131, 142]. Igal RA has reviewed numerous 
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experimental, clinical and epidemiological data on the role of SCD1 activity in tumor 
phenotype and has hypothesized a model for its implication in cancer, as presented in 
Figure 1.10.  
 
 
 
Figure 1.10: A hypothetical mechanism for the crosstalk between oncogenic signals and metabolic 
pathways controlled by SCD1 in cancer onset and progression. MUFA, monounsaturated fatty 
acids; SFA, saturated fatty acids; SCD, Stearoyl-CoA Desaturase. Modified from Igal RA (2016). 
 
According to this hypothesis, SCD1 may regulate important signaling pathways that are 
involved in the survival and proliferation of tumor cells and supports the concept of the 
dynamic interplay between oncogenic signals and metabolic pathways. The enhanced 
desaturase activity leads to increased MUFA to SFA ratio in plasma membrane, thus 
influencing the fluidity of non-raft microdomains. These relatively more fluid membrane 
microdomains may favor the oncogenic transformation through the modulation of signaling 
platforms, such as the PI3K/Akt, mTORC, AMPK and Wnt pathways [143-146]. In 
addition, the conversion of SFA into MUFA by the SCD1 might have a protective impact 
on cancer cells by preventing lipotoxicity events caused by SFA excess that would lead to 
cell stress response and the consequent programmed cell death [147, 148]. 
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Other enzymes, involved in endogenous FA biosynthesis, have been reported to be 
important in tumorigenesis. For instance, the ATP citrate lyase (ACLY), which is activated 
by Akt, has been proved to be crucial for tumor development and progression in in vitro 
and in vivo studies [149, 150]. The acetyl-CoA carboxylase (ACC) induces cancer growth 
in prostate cancer cells [151]. Furthermore, the sterol regulatory element-binding proteins 
(SREBPs), which are transcription factors controlling the expression of genes involved in 
FA synthesis, are overexpressed in cancer [42, 152]. Both SREBP and ACC are suppressed 
by AMPK [153]. Finally, cancer cells form more lipid droplets than normal cells [154]. 
Finally, it is worth noting that fatty acid synthesis in cancer cells is mainly regulated 
through hormones or oncogene signaling, and not by the diet like in the case of lipogenic 
tissues. Although cancer cells are able to incorporate exogenous fatty acids, they are 
characterized by a highly active de novo fatty acid biosynthesis. This increased FA 
production could be attributed to the limited availability of nutrients in tumor 
microenvironment.  
 
1.2.2 Fatty acid composition of tumor patients’ erythrocytes 
As described previously, the fatty acids exert multifaceted roles on the development and 
progression of cancer [72]. In this regard, several studies have examined the association 
between the fatty acid composition in human tissues and the risk of tumor occurrence [133, 
155, 156]. The families of SFA and MUFA may be considered as markers of FA metabolic 
turnover, since they are endogenously synthesized. On the other hand, PUFA could 
represent the dietary FA intake since they are either essential or semi-essential lipid species 
[104]. Being an easily withdrawn human tissue, blood has been often examined for its fatty 
acid composition. The Table 1.2. summarizes the results of studies analyzing the 
correlation between RBC membrane FA content and tumor risk. Although some 
controversies arised among the reported findings, some trends can be presumed in the FA 
composition of erythrocyte’s phospholipids and cancer risk. Increased levels of oleic, SFA 
and omega-6 PUFA content show a positive correlation with tumor occurrence. In contrast, 
EPA, DHA and total omega-3 PUFA content are inversely associated to cancer risk. 
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Table 1.2: Summary of published studies examining the association between fatty acid composition 
in erythrocyte’s membrane and tumor risk. DGLA, dihomo-γ-linolenic acid; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acids; GLA, γ-linolenic acid; LA, 
linoleic acid; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, 
saturated fatty acids. 
Cancer 
type 
Positive 
correlation 
Negative 
correlation 
N 
Country/
State 
Reference 
Breast 
Oleic 
MUFA 
PUFA total 
SFA/MUFA 
71 Italy Pala et al. [157] 
Breast 
Palmitic 
Palmitoleic 
Vaccenic 
GLA  
EPA 
PUFA-ω3 
SFA/MUFA 
322 China Shannon et al. [158] 
Breast 
SFA 
SFA/PUFA-ω3 
EPA 
DHA 
PUFA-ω3 
103 Japan Kuriki et al. [159] 
Breast - 
LA 
Arachidonic 
46 Russia Zaridze et al. [160] 
Colorectal 
(adenoma) 
Oleic 
DGLA 
EPA 
DHA 
328 France Cottet et al. [161] 
Colorectal 
(adenoma) 
Arachidonic EPA 904 Tennessee Rifkin et al. [162] 
Colorectal - PUFA-ω3 13 Italy Coviello et al. [163] 
Colorectal 
Palmitic 
SFA 
SFA/PUFA 
Arachidonic 
DHA 
PUFA total 
74 Japan Kuriki et al. [164] 
Colorectal - EPA 61 Japan Okuno et al. [165] 
Gastric - 
DHA 
PUFA-ω3  
179 Japan Kuriki et al. [166] 
Gastro-
intestinal 
Stearic 
DHA 
PUFA-ω3 
Oleic 
LA 
MUFA 
50 China Lin et al. [167] 
Multiple 
myeloma 
SFA 
PUFA-ω6 
MUFA 
PUFA-ω3 
trans FA 
43 Poland Jurczyszyn et al. [168] 
Ocular 
melanoma 
- Stearic/Oleic 19 UK Aclimandos et al.[169] 
Skin SCC Arachidonic 
Palmitic 
Palmitoleic 
335 Arizona Harris et al. [170] 
Various Oleic Stearic 255 Kansas Mikirova et al. [171] 
Various - Stearic/Oleic 60 UK Wood et al. [172] 
 
A parallel analysis of breast tissue and erythrocytes FA composition of women with breast 
cancer indicated a positive association regarding the long-chain PUFA-ω3, while no 
significant correlation was revealed for their diet-derived precursor, alpha-linolenic acid 
[173]. Furthermore, the examination of the breast adipose tissue indicated that linoleic and 
arachidonic acid were increased in women with breast cancer compared to control group 
[174]. Another comparative study examined the differences on the tumor tissue’s FA 
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content between patients with metastatic and non-metastatic colorectal cancer [175]. 
Notarnicola et al. showed that metastatic patients were characterized by lower levels of 
EPA and higher percentages of GLA in tumor tissues. However, no significant differences 
were revealed in their RBC membrane profiles. Finally, both the white blood cells (WBC) 
and the red blood cells of chronic leukemia patients presented lower saturation indices 
(stearic:oleic) than controls [176]. Similarly reduced saturation index has been also found 
in malignant liver neoplasms [177]. 
 
1.2.3 Antineoplastic agents affecting membrane’s structure and properties 
Like other xenobiotics, several antineoplastic agents have been recently reported to 
influence the physical and functional properties of the plasma membrane, such as fluidity 
and composition [178-181]. The changes in plasma membrane characteristics trigger the 
activation of signaling pathways that in turn influence the cell fate [179]. Since 
chemotherapy-induced cell death is mediated via signaling through plasma membrane (e.g. 
lipid rafts involving the death receptor pathway), attention has been given to the changes 
that membranes undergo upon cellular death [178, 181]. Therefore, affecting the 
metabolism of plasma membrane’s building blocks might influence the tumor cellular 
growth and the related lipid signaling. For example, it has been reported that the regulated 
biosynthesis of SFA and MUFA can influence the biophysical properties of the tumor cell 
membrane and thus the signaling pathways related to cellular growth and survival [3, 182-
185]. 
Cisplatin, a common antitumoral drug, has been proven to induce membrane fluidification 
and clustering of lipid rafts and Fas death receptors in human colon cancer cells [186, 187]. 
All these effects were reversed in cisplatin treated cells when membrane-stabilizing agents 
were used, without affecting the drug uptake and its DNA cleavage efficacy [187]. In 
addition to altered membrane fluidity, cisplatin as well as gemcitabine treatment promoted 
the intracellular acidification through the inhibition of NHE1 (Na+/H+ membrane 
exchanger-1), which led to the aSMase (acid sphingomyelinase) activation and the 
subsequent ceramides formation [187-189]. Liang et al. demonstrated a positive 
association between membrane saturation degree and resistance to cisplatin treatment in 
lung adenocarcinoma cells [190]. Many chemotherapeutics, such as doxorubicin, 
tamoxifen and 3,6-dihydroxyflavone, have been also indicated to influence membrane’s 
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fluidity with consequent effects on their cytotoxicity [191-198]. Interestingly, a cross talk 
between chemical-induced cellular membrane effects and drug’s main mechanism has been 
suggested to be important for the final outcome of chemical exposure [180].  
Bleomycin is another widely known antineoplastic agent known to react with the 
membrane lipids [199-201]. Its therapeutic use is based, alike the famous cisplatin 
chemotherapy, on its ability to cleave DNA [202, 203]. However, such metallo-antibiotics 
mediate oxidation of other cellular molecules, such as lipid peroxidation [204, 205]. More 
specifically, bleomycin has been found to induce in vitro a profound membrane remodeling 
at the level of the fatty acid constituents, which includes an increase of saturated fatty acid 
(SFA) content with a parallel decrease of monounsaturated and polyunsaturated fatty acids 
(MUFA and PUFA) [199]. Furthermore, studies on liposomes made of SFA, MUFA and 
PUFA-containing phospholipids have shown the occurrence of lipid isomerization, as well 
as the PUFA consumption, under biomimetic conditions of free radical and oxidative stress 
[200]. Differential fatty acid distribution in phospholipids has been also observed in 
hepatocellular and colorectal cancer cells treated with non-toxic doses of 5-fluorouracil and 
doxorubicin. In particular, chemotherapeutics-treated cells showed lower levels of SFA and 
higher content of PUFA in both cell lines [206]. Modifications of the membrane structure 
have been reported in minerval (2-hydroxyoleic acid)-treated cells [207, 208]. Minerval is 
a potential antitumoral drug that, contrary to conventional strategies, serves as a 
membrane’s structure modifier by increasing the propensity of phospholipid bilayer to 
assemble into nonlamellar phases [208]. This reorganization leads to the localization of 
PKC (protein kinase C) to the membrane and subsequent cellular growth arrest through 
p21 activation [208]. Llado et al. proposed that minerval-induced membrane reorganization 
induces the aggregation of Fas death receptors, thus leading to the activation of the extrinsic 
pathway of programmed cell death [207]. 
 
1.2.4 Fatty acid supplementation in cancer prevention and co-adjuvant treatment 
According to the available epidemiological data, the elevated consumption of fish oil as 
well as the dietary PUFA-ω3 supplementation decrease the risk of various cancer types, 
such as breast, prostate, pancreatic and colorectal [209-213]. The low PUFA-ω3 to PUFA-
ω6 ratio has also been associated to increased cancer incidence [214]. On the contrary, a 
meta-analysis of numerous epidemiological studies, including 900,000 subjects, proved 
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that the high consumption of total, saturated and trans fatty acids increase ovarian risk 
[215]. Several in vitro and in vivo studies have been carried out aiming to elucidate the 
mechanisms underlying PUFA’s protective role against cancer [216, 217]. These 
mechanisms involve a big range of target molecules with various effects on cellular 
survival, proliferation and inflammation [218]. For instance, PUFA-ω3 supplementation 
alters the size and composition of membrane lipid rafts which in turn affects the function 
of lipid rafts proteins and the associated downstream signaling [219]. 
 
 
Figure 1.11: Hypothetical mechanisms for tumor promotion and suppression by PUFA-ω6 and 
PUFA-ω3, respectively. Dietary modulation of ω-6/ω-3 ratio may reduce the PLA2-catalyzed 
release of ARA and the production of the pro-inflammatory eicosanoids, that are involved in tumor 
initiation and progression. Modified from Larsson (2004) [218] 
 
More particularly, DHA exerts its anti-proliferative properties by inducing the ROS 
production and subsequent apoptosis, suppressing the Wnt/β-catenin pathway, and 
decreasing the production of pro-angiogenic factors in pancreatic cancer cells [220-222]. 
Hawkins et al. have proved a positive correlation between the number of double bonds and 
PUFA-induced apoptosis of leukemic and pancreatic cancer cells [223]. In the case of colon 
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cancer, dietary fish oil supplementation is accompanied by limited synthesis of secondary 
bile acids, which are implicated in the colon carcinogenesis and their levels have been 
found increased in tumor patients [224, 225]. Furthermore, animal models that received a 
PUFA- ω3 enriched diet showed lower activity of PLA2 and COX-2 in colonocytes, thus 
limiting the ARA release and prostaglandins synthesis, respectively [224, 226, 227]. 
PUFA-ω3 have also been proved to suppress the expression and activity of proteins that 
are involved in cell proliferation and apoptosis, such as the protein kinase C, Ras, Bcl-2 
and insulin-like growth factor-II in cell lines and animal models [217]. Based on the 
demonstrated protective effects of the essential PUFA-ω3 against cancer in animal and cell 
culture models and the fact that Western diet includes an unbalanced omega-6 to omega-3 
ratio, the clinical use of ω-3 supplementation for tumor prevention has been suggested 
[228-230]. 
Furthermore, the consumption of PUFA-ω3 has been proposed as a potential adjuvant and 
nutritional support for the cancer patients since they exhibit a particular metabolism and 
have specific nutritional requirements [231, 232]. FA administration (mainly EPA and 
DHA) aims at weight loss stabilization, limitation of side effects, nutritional status 
improvement, as well as enhancement of tumor treatment outcome [228]. As far as the 
pharmacological success is concerned, PUFA-ω3 have gained attention thanks to their 
effect on inflammatory and immune response [233]. Furthermore, dietary enrichment of 
PUFA-ω3 may reduce the proportion of PUFA-ω6 and limit the synthesis of the pro-
inflammatory eicosanoids [228]. DHA supplementation in breast cancer patients 
undergoing anthracycline treatment improved the overall survival and the side effects 
tolerance [234]. Lipid replacement therapy (LRT), as suggested by Nicolson, involves the 
use of membrane lipids along with antioxidants as food supplements to replace damaged 
lipids [235]. Cells have the ability of rapid membrane remodelling that gives them the 
opportunity to alter the phospholipid composition based on the intracellular FA pool [79]. 
Impaired lipids can originate from intracellular ROS reactivity and alter membrane 
properties, such as fluidity, thus impeding its proper function like ion exchange, transport, 
enzymatic activity [236]. The substitution of oxidatively damaged membrane lipids with 
unoxidized ones contributes to the repaired structure and function of cellular membranes. 
LRT has been proved efficient on patients with chronic fatigue and fibromyalgia syndrome 
[229, 237]. Colodny et al. conducted a clinical study that examined the efficacy of lipid 
replacement therapy on decreasing the chemotherapy-induced side effects. Human subjects 
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consumed Propax with NTFactor®, which is a commercially available food supplement 
that contains essential fatty acids and antioxidants, amongst others. Patients with advanced 
colon, pancreatic or rectal cancer that received Propax before and during chemotherapy 
demonstrated fewer incidences of fatigue, nausea and other quality life indicators [238].
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2. Materials and methods 
2.1 Materials 
2.1.1 Reagents 
Cu-TPMA-Phen was prepared by Fantoni N. et al. at School of Chemical Sciences, Dublin 
City University (DCU) according to published procedure [239]. Polymeric nanocontainers 
and encapsulated form of Cu-TPMA-Phen were prepared by Toniolo G. at the Institute of 
Nanoscience and Nanotechnology, N.C.S.R. “Demokritos”. Cell viability was measured 
using the colorimetric CellTiter 96®Aqueous One Solution Cell Proliferation Assay 
(Promega). The CellTiter 96® Aqueous One Solution Reagent contains the tetrazolium 
compound 3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2Htetrazolium (MTS), and an electron coupling reagent (1methoxy phenazine 
methosulfate—PMS). The activity of caspases -8, -9, -3/7 was evaluated using the 
luminescent assays Caspase-Glo™ 8 and Caspase-Glo™ 9 Caspase-Glo™3/7 (Promega 
Corporation, Fitchburg, Wisconsin, USA). Morphological membrane changes were 
detected using Annexin V-EGFP/PI detection kit (Biovision, Mt. View, CA, USA). The 
human neuroblastoma-derived NB100 cell line [20] and the MCF7 cell line (ATCC number 
HTB-22™) were from long term culture in the Department of Experimental, Diagnostic 
and Specialty Medicine, University of Bologna, IT. U87MG brain glioblastoma was 
obtained from the American Type Culture Collection (ATCC). RPMI 1640, Fetal Bovine 
Serum (FBS), L-Glutamine and penicillin-streptomycin solution were purchased from 
Sigma-Aldrich (San Louis, MO, USA). Trypsin/EDTA was from BioWhittaker Europe, 
Verviers, Belgium. Trypan blue (BioWhittaker, Vervies, Belgium) was used for the cell 
viability evaluation during standard cell seeding. Flasks and plates were from Falcon 
(Franklin Lakes, NJ, USA). All the other cell culture reagents were from Sigma-Aldrich. 
The water used was prepared by the device Milli-Q (Millipore, Milford, MA USA) and 
was acquired at a resistance value of 18 ΜΩ at the source. Silica TLC plates were purchased 
from Macherey-Nagel. Chloroform, n-hexane, methanol and phosphate buffer were 
purchased from Sigma-Aldrich (San Louis, MO, USA). All compounds were used without 
further purification. Other reagents used were from Merck (Darmstadt, Germany), Carlo 
Erba (Milano, Italy) and Sigma-Aldrich. 
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2.1.2 Instruments 
Cell viability was evaluated by measuring absorbance at 492 nm by a microtiter plate reader 
Multiskan EX (ThermoLabSystems, Basingstoke, UK). Phase contrast microscopy was 
carried out with a Wilovert Standard PH 20 (HUND, Wetzlar, Germany) and a digital 
camera from Motic Microscopes, China. Protein concentration and NADPH-cytochrome c 
reductase activity were measured by the spectrophotometer UVICON 860 (Kontron 
Instruments, Milano, IT). For the luminescence acquisition the luminometer Fluoroskan 
Ascent FL (Labsystem, FI) was used. Flow cytometry analysis was performed on a 
FACSaria BD Analyser using FACSDiva software (Becton, Dickinson and Company, 
Franklin Lakes NJ, USA). Fatty acid analysis was performed on a 6850 Series II gas 
chromatography apparatus using ChemStation software (Agilent 6850, Milan, IT). 
 
2.2 Methods 
2.2.1 Cell cultures  
The activity of Cu-TPMA-Phen was assayed on NB100 cells that derived from a human 
primary neuroblastoma [20]. Cells were cultured as a monolayer at 37 °C in a humidified 
atmosphere at 5% CO2 in complete medium (RPMI 1640 supplemented with 10% heat-
inactivated FBS, 2 mM L-Glutamine, 100 units/mL Penicillin, 0.1 mg/mL Streptomycin). 
Cultures were maintained in the log phase of growth with a viability >95% and checked 
for the absence of Mycoplasma infection. The viability was checked before each 
experiment by Trypan blue dye exclusion. Before any treatment cells were incubated for 
24 h.  
 
2.2.2 Cell viability assay  
Cell viability was evaluated using the colorimetric CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay. Cells (2×104/well) were seeded in 96-well microtiter plates in 100 
µL of complete medium. After 24 h, the cells were incubated in the absence or in the 
presence of Cu-TPMA-Phen at various concentrations in complete medium. After the 
indicated times, 20 µL/well of the kit solution was added. After 1-2 h of incubation at 37 
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°C, the absorbance at 492 nm was measured by a microtiter plate reader Multiskan EX 
(Thermo Labsystems, Helsinki, Finland). In continuous incubation experiments, cells were 
exposed to Cu-TPMA-Phen for 24, 48 and 72 h at a concentration ranging from 0.1 to 30 
µM. In pulse and chase experiments, cells were treated with Cu-TPMA-Phen for 2 h at a 
concentration ranging from 0.1 to 100 µM and then incubated in complete medium for a 
total time of 24 and 48 h. Half-maximal effective concentration (EC50) was determined by 
standard slope analysis without normalization.  
 
2.2.3 Evaluation of apoptosis  
The cell death pathway (apoptotic vs necrotic) was assessed using a flow cytometry 
AnnexinV/PI detection kit and by a luminescent reagent detecting caspase activity [240].  
For flow cytometry experiments, cells (2×105/3ml) were seeded in 25-cm2 flasks and, after 
24 h incubation with 5 µM Cu-TPMA-Phen, the cells then, were treated with Annexin 
VEGFP and PI and analysed by flow cytometry. The apoptotic (AnnexinV+/PI−), necrotic 
(AnnexinV−/PI+) and late stage apoptotic cells (AnnexinV+/PI+) were counted by the 
instrument and reported on scatter plots. The caspase-3/7 activity was assessed by the 
luminescent Caspase-Glo™3/7 Assay. Briefly, cells (2×103/well) were seeded in 96-well 
microtiter plates in 100 µL of complete medium. After 24 h, cells were treated with 5 μΜ 
Cu-TPMA-Phen. After further 24 h incubation, 100 µL/well of caspase kit reagent was 
added. After 20 min the luminescence was measured by a Fluoroskan Ascent FL (Thermo 
Labsystems), and the values were normalized to cell viability. The morphological features 
of the treated cells were analyzed through phase contrast microscopy, directly in 96-well 
plate, using an inverted microscope Nikon Eclipse TS100 (Nikon, Melville, NY, USA).  
 
2.2.4 Microsomes isolation 
The microsomal membrane fraction was isolated by sequential centrifugation. For this 
purpose, >2×108 NB100 cells were cultured in near confluent monolayer. The followed 
steps for the extraction and isolation of microsomes (crude endoplasmic reticulum) are 
described below: 
Sample homogenization  
1. Cell detachment with trypsin/EDTA using standard procedures. 
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2. Cell centrifugation at 600 × g for 5 min. 
3. Washing of cell pellet with 1 mL ice-cold PBS. 
4. Cell centrifugation at 600 × g for 5 min (at 4 °C) and measurement of packed cell 
volume (PCV). 
5. Discard of the supernatant. Cell pellet resuspension in cold 1 × Hypotonic 
Extraction Buffer equivalent to 3 times the PCV and cell incubation for 20 min at 
4 °C (cell swelling). 
6. Cell centrifugation at 600 × g for 5 min. Supernatant removal by aspiration. 
Measurement of the new PCV.  
7. Addition of a volume of the 1 × Isotonic Extraction Buffer equivalent to 2 times 
the «new» PCV volume and transfer to a 7 mL Dounce homogenizer. 
8. Cell breakage with 10 strokes of the Dounce homogenizer. 
9. Addition of more 1 × Isotonic Extraction Buffer (1.5 mL per mL of PCV). 
Pipetting of the cell slurry up and down several times for full suspension of the 
homogenate. 
Endoplasmic reticulum isolation 
1. Transfer of the homogenate to a microcentrifuge tube and vortex for 30 s, 
followed by incubation on ice for 1 min.  
2. Centrifugation at 10.000 × g for 15 min, at 4 °C. 
3. Transfer of the supernatant to a new, pre-chilled microcentrifuge tube and 
centrifugation at maximum speed (>100.000 × g) for 60 min, at 4 °C. Following 
centrifugation, discard of the supernatant, taking care to preserve only the light 
beige/pink opalescent (microsomal) pellet. 
4. Washing of the pellet gently with 1× Isotonic Extraction Buffer (500 μL per mL 
of PCV) and discard of excess buffer.  
5. Resuspension of the microsomal pellet in ice-cold 1× Isotonic Extraction Buffer 
(500 μL per mL of PCV) and determination of the total microsomal protein 
concentration.  
The microsomal solution was aliquoted and stored at -80 °C. 
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Buffer Recipes 
Isotonic Extraction Buffer 1× Hypotonic Extraction Buffer 1× 
HEPES, 10 mM (pH 7.8) HEPES, 10 mM (pH 7.8) 
Sucrose, 250 mM EGTA, 1 mM 
EGTA, 1 mM KCl, 25 mM 
KCl, 25 mM Protease inhibitors (1%) 
Protease inhibitors (1%)  
 
 
2.2.5 Protein concentration 
Protein concentrations were determined by the method of Bradford. Protein calibration 
curve was prepared with known concentrations of bovine serum albumin (BSA) solution.  
 
Figure 2.1: BSA calibration curve for the calculation of protein concentration.  
 
2.2.6 Microsomes activity 
The functionality of isolated microsomes was evaluated by measuring the activity of 
NADPH cytochrome c reductase, which is widely used as an endoplasmic reticulum 
marker. The activity of this enzyme in purified microsomes was determined using the 
Cytochrome c Reductase Assay Kit, SIGMA. It is a colorimetric method, which depends 
on the reduction of cytochrome c by NADPH-Cytochrome c reductase in the presence of 
NADPH. The reduced cytochrome c results in the formation of distinct bands at 550 nm 
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and the rate of absorbance (550 nm) increase is estimated. The calculated activity of 
NADPH cytochrome c reductase at the extracted microsomes was 0.261 units/mL. 
 
Figure 2.2: Cytochrome c reductase (NADPH) activity for the analysis of functionality of extracted 
crude endoplasmic reticulum (microsomes).  
 
2.2.7 SCD1 activity assay 
The reaction mixture for the stearoyl-CoA desaturase activity included the following: 60 
μM stearoyl-CoA, 2 mM NADH in 10 mM potassium phosphate (pH 7.2), 0.1 M potassium 
phosphate (pH 7.2), and 100 μg of microsomal protein in a final volume of 100 μl. The 
microsomal fractions were incubated with the reaction mixture at 37 °C for 10 min under 
shaking. The reaction was terminated by the addition of isopropanol. The mixture was then 
evaporated, and the reaction products were trans-esterified for the consequent analysis with 
gas chromatography. SCD1 activity was estimated using the product-to-precursor fatty acid 
ratio, [oleic (18:1-Δ9) / stearic (18:0)] [241, 242]. 
 
2.2.8 Phospholipid Extraction 
To analyze the effect of Cu-TPMA-Phen treatment on membrane fatty acids, 0.8×106 cells 
were seeded in 25 cm2 flasks in 5 mL of complete medium. After 24 h of incubation, 
medium supplemented with 5 μΜ Cu-TPMA-Phen was added. Cells were harvested and 
washed twice with ice-cold PBS. The cell pellet was resuspended in 1 mL milli-Q H2O and 
centrifuged at 14.000 rpm for 15 min at 4 °C. For mice RBC analysis, blood was withdrawn 
from deeply ether-anaesthetized animals and collected in K2EDTA treated tubes. 200 µL 
whole blood from mice were centrifuged at 4.000 rpm for 5 min at 4 °C to remove plasma 
Materials and Methods 
 
38 
 
fraction. The red blood cell (RBC) pellet was then resuspended in pure water and 
centrifuged at 14.000 rpm for 15 min at 4 °C. In both cases, membrane pellets were 
dissolved in chloroform:methanol (2∶1) and Folch extraction method followed.  
 
2.2.9 Thin layer chromatography 
Lipid extract was examined by thin layer chromatography to determine the purity of the 
phospholipid fraction. Silica plates were used as the stationary phase, while the solvent 
system n-hexane/diethyl ether/acetic acid (70:30:1) consisted the mobile phase. Standard 
reference molecules were used for the recognition of phospholipids, cholesterol, 
triglycerides and cholesteryl esters in the lipid extract. TLC plates were stained with ceric 
ammonium molybdate solution (CAM) and spots were formed after heating. 
 
2.2.10 Gas chromatographic fatty acid analysis 
Fatty acid derivatization 
The phospholipid extracts were treated with 0.5 M KOH in methanol for 10 min at room 
temperature under stirring for the derivatization of fatty acid residues of the phospholipids 
into their corresponding fatty acid methyl esters (FAME). The acyl-CoA moieties were 
treated with trimethylsulfonium hydroxide (TMSH) in methyl tert-butyl ether (MTBE) 
anhydrous (1:2) at 120 °C for 3 min [243]. After transesterification, FAME were extracted 
with n-hexane; n-hexane phase was dehydrated with anhydrous Na2SO4, evaporated and 
analyzed in GC.  
 
GC parameters 
FAME were analyzed by gas chromatography (Agilent 6850, Milan) equipped with a 60 m 
x 0.25 mm x 0.25 μm (50%cyanopropyl)-methylpolysiloxane column (DB23, Agilent, 
USA), a flame ionization detector (FID), with injector temperature at 230 °C and split 
injection 50:1. Oven temperature started from 165 °C, held for 3 min, followed by an 
increase of 1 °C/min up to 195°C, held for 40 min, followed by a second increase of 10 
°C/min up to 240 °C, and held for 10 min. A constant pressure mode (29 psi) with helium 
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as a carrier gas was used. Methyl esters were identified by comparison with the retention 
times of commercially available standards or trans fatty acid references, obtained as 
described elsewhere [244]. The list of the examined FAME (corresponding to 
chromatographic peak areas >97%) in membrane PL are reported as % relative percentages 
of GC area. 
 
Figure 2.3: Representative GC chromatogram of FAME for fatty-acid based membrane lipidomic 
analysis.  
 
The detection and quantitation limit were determined by comparing measured signals from 
the chromatograms of samples with known low concentrations of analyte with those of 
blank samples. For the detection limit, the acceptance criterion was a signal/noise ratio of 
minimum 3:1, while for the quantitation limit the acceptance criterion was a signal/noise 
ratio of minimum 10:1. 
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Fatty acid indices calculation 
Membrane’s desaturation degree and susceptibility to peroxidation were estimated using 
the Unsaturation Index (UI) and Peroxidation Index (PI), respectively. The indices were 
calculated using the following formulas [245, 246]: 
 
Unsaturation Index (UI) = (% monoenoic × 1) + (% dienoic × 2) + (% trienoic × 3) + (% 
tetraenoic × 4) + (% pentaenoic × 5) + (% hexaenoic × 6) 
Peroxidation Index (PI) = (% monoenoic × 0.025) + (% dienoic × 1) + (% trienoic × 2) + 
(% tetraenoic × 4) + (% pentaenoic × 6) + (% hexaenoic × 8) 
 
Quantification 
The external standardization method was applied for the GC quantification and it was 
performed within the linear range of response. Calibration curves (GC area vs FA 
concentration) were obtained using standard solutions of known concentration for each FA 
moiety. Calibration curves were considered linear when the coefficient factor R2 was equal 
to or greater than 0.995. Representative calibration curves are depicted below: 
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Figure 2.4: Calibration curves of four representative fatty acid methyl esters (FAME): (A) the 
saturated methyl palmitate (16:0); (B) the monounsaturated methyl oleate (18:1 c9); (C) the ω6 
polyunsaturated methyl linoleate (18:2 ω6) and (D) the ω3 polyunsaturated methyl-(22:6 ω3). 
 
Analyte’s concentration was calculated by the following expression: 
 
𝐶𝑥 =
𝐶𝑠𝑡𝑑 × 𝐴𝑥
𝐴𝑠𝑡𝑑
 
 
where, 
Cx: the concentration of the x-FA in the sample 
Cstd: the concentration of the x-FA in the standard solution 
Ax: the area of the x-FA from the sample chromatogram 
Astd: the area of the x-FA from the standard chromatogram 
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2.2.11 Animal studies  
Mice were housed at SOL-GEL laboratory, Institute of Nanoscience and Nanotechnology 
at the National Centre for Scientific Research "Demokritos". Female severe combined 
immunodeficient (SCID) mice and normal healthy Swiss mice were housed in groups of 
three per cage under positive pressure in polysulfone type IIL individual ventilated cages 
(Sealsafe, Tecniplast, Buguggiate, Italy). Room temperature and relative humidity were 24 
± 2 °C and 55 ± 10 % respectively. All animals in the facility were screened regularly 
according to the Federation of European Laboratory Animal Science Associations’ 
recommendations and were found free of the respective pathogens. Mice had ad libitum 
access to water and food. SCID mice were inoculated with U87MG human brain 
glioblastoma cells as previously described [247]. Humane endpoints were predetermined 
(tumor volume over 1,2 cm, severe compromise of the welfare of the animals, and body 
weight loss over 20%). The tumor volume and mice weight were monitored once a week 
with an automatic caliper and scale. The tumor volume, body weight, and the survival rate 
were calculated at different time intervals. Ethical statement: All protocols were approved 
by the General Directorate of Veterinary Services Athens, Greece according to Greek 
legislation (Presidential Degree 160/1991) in compliance with the European Economic 
Community Directive 609/1986, and Law 2015/1992 for the protection of vertebrate 
animals used for experimental or other scientific purposes, 123/1986.  
  
2.2.12 Xenografts model construction  
U87MG brain glioblastoma cells were cultured as monolayers at 37 °C in a humidified 
atmosphere of 5% (v/v) CO2 and 95% relative humidity. Cells were seeded in 75 cm
2 
plastic tissue culture flasks and cultured in DMEM supplemented with 10% FBS, washed 
with phosphate buffered saline (PBS) and were harvested by trypsinization with 0.05% 
(w/v) trypsin in PBS containing 0.02% (w/v) EDTA. SCID mice were xenografted at two 
weeks of age with U87MG cells subcutaneously on the right side of the thorax. Tumors 
were inoculated after injection of 6x106 U87MG cells in SCID mice, which were 
previously grown in DMEM. 
 
 
Materials and Methods 
 
43 
 
2.2.13 Statistical analysis  
Statistical analysis was conducted using GraphPad Prism 7.02 software for Windows, 
GraphPad Software, La Jolla California USA. All measurements were performed in 
replicates and the data were expressed as the mean ± standard deviation (SD). Statistical 
significance was based on 95% confidence intervals (p≤0.05). 
Comparison of two groups 
For the comparison of two groups, an unpaired Student’s t-test was employed to analyze 
the data.  
Comparison of three or more groups 
For the comparison of three or more groups, data were analyzed by one-way analysis of 
variance (ANOVA) combined with either Tukey’s posthoc test or Dunnett's multiple 
comparison tests for the statistically significant results. 
Curve fitting and EC50 calculation 
For cell viability curves, experimental values were fitted to a nonlinear regression model. 
Half-maximal effective concentration (EC50) was determined by standard slope (Hill factor 
1.0) analysis without normalization using log[concentration] vs response equation. 
Cell viability curves comparison 
Comparison of diverse cell viability curves was conducted with F test (sum-of-squares). 
The statistically significant difference between the EC50 values was evaluated based on the 
obtained p-value.
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3. The copper complex: Cu-TPMA-Phen 
3.1 Background and Objectives 
The project described in the present chapter was performed in collaboration with the groups 
of Prof. Dr. A. Kellett at School of Chemical Sciences, Dublin City University (DCU) and 
Dr. E. Efthimiadou at the Institute of Nanoscience and Nanotechnology, N.C.S.R. 
“Demokritos”. The overall goal of this research project was to develop novel copper 
complexes and study their cytotoxic properties in relation with their effect on cell 
membrane lipidome. The chemical compound here studied and its encapsulated form in a 
drug delivery system were respectively provided by our collaborators at DCU and at the 
NCSR “Demokritos”. The below-described research activities were carried out in the 
laboratory of Prof. Dr. A. Bolognesi in the Department of Experimental, Diagnostic and 
Specialty Medicine (DIMES) at University of Bologna and in the CNR/spin-off company 
Lipinutragen. 
The novel copper complex developed at DCU was envisioned to be a gene silencing agent 
by acting as a chemical nuclease. Thanks to their intrinsic redox properties, the copper 
complexes are interesting compounds for oxidative-based therapeutic strategies [248, 249]. 
Among antitumoral active metallodrugs, copper(II)-complexes are of particular interest 
since they can become redox-active upon their in vivo reduction to Cu(I) [250, 251]. In 
parallel, when combined with DNA binding properties, they can mediate oxidatively-
induced DNA-strand breaks and eventually result in genome damage and instability [252-
254]. Although copper is essential for cellular redox metabolism, its homeostasis must be 
fine-tuned since free copper ions can catalyze the generation of reactive oxygen species 
(ROS), such as superoxide (O2·ˉ) and hydroxyl (·OH) radicals. Indeed, Cu(I) is unstable 
under physiological conditions and it is oxidized into Cu(II) by O2 or H2O2 via the Fenton 
reaction (Figure 3.1). As a consequence, the formed ROS cause oxidative stress to cells 
thus resulting in the damage of various biomolecules such as DNA, proteins and lipids 
[255]. Among the non-specific strategies for cancer chemotherapy, chemical agents with 
the ability to cleave DNA are widely used, such as cisplatin (metal-containing compound) 
and bleomycin (metal-binding site containing compound) [256, 257]. Based on their 
biological and chemical properties, copper complexes can act as artificial metallo-
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nucleases (AMNs) for specific gene disruption and therefore represent promising 
anticancer agents [254, 258]. 
 
 
Figure 3.1: Fenton reaction; copper(I) is oxidized by oxygen to copper(II), forming superoxide and 
hydroxyl radicals in the process. 
 
Like other xenobiotics, AMNs have been recently reported to influence the characteristics 
of the plasma membrane, such as fluidity and composition [188, 259]. The changes in 
plasma membrane characteristics trigger the activation of signaling pathways that in turn 
influence the cell fate [179]. Since chemotherapy-induced cell death is mediated via 
signaling through plasma membrane (e.g. lipid rafts involving the death receptor pathway), 
attention has been given to the changes that membranes undergo upon cellular death [178, 
181]. Moreover, it has been suggested that a cross talk between chemical-induced cellular 
membrane effects and DNA damages may be important for the final outcome of chemical 
exposure [180]. Cell membranes are built by phospholipids, which are fatty acid-
containing lipid species responsible for the membrane’s structural, organizational and 
functional properties. The fatty acids and their metabolism are of vital significance for 
cancer cells [105, 260]. Indeed, because of their active proliferation, cancer cells need a 
substantial amount of newly biosynthesized lipids. Consequently, affecting the metabolism 
of these building blocks might influence the tumor cellular growth and the related lipid 
signaling. For example, it has been reported that the regulated biosynthesis of SFA, such 
as palmitic acid (16:0) or stearic acid (18:0), and their subsequent desaturation to MUFA 
(palmitoleic acid (delta-9 16:1) and oleic acid (delta-9 18:1)), can influence the biophysical 
properties of the tumor cell membrane and thus the signaling pathways related to cellular 
growth and survival [3, 182-185]. Since the fatty acids are part of our dietary intakes, their 
balance can also impact the drug outcomes and interactions with other organelles. In this 
regard, fatty acid-based membrane lipidomics could in principle represent a valuable tool 
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in cancer therapy by providing insights on how the rearrangement of cell membranes of a 
tumor cell population might enhance the outcome of a given treatment [185, 235].  
In the present research project, the novel Cu(II) complex [Cu(TPMA)(Phen)](ClO4)2 was 
studied being used both as a free compound and under an encapsulated form within 
polymeric nanoparticles, thus allowing for the comparison with the free drug. In vitro 
experiments were carried out in the neuroblastoma derived cell line NB100 and in the 
breast carcinoma cell line MCF7. The cytotoxicity of both free and encapsulated complex 
was determined and the cell death pathways were analyzed with parallel monitoring of 
caspase activation. NB100 cells were treated with EC50 (half maximal effective 
concentration) doses of copper complex and membrane fatty acids were analyzed by gas 
chromatography. Inhibitors of apoptosis and necroptosis and scavengers of oxidative stress 
were tested to evaluate their protective effect against copper’s cytotoxicity and membrane 
remodeling. Finally, we were interested to test whether fatty acid supplementation could 
influence the cell response to copper complex exposure. 
 
 
3.2 Molecular structure  
In the current project, we studied the biological effects of the synthetic chemical nuclease 
[Cu(TPMA)(Phen)](ClO4)2 (Cu-TPMA-Phen)], where TPMA = tris-(2-
pyridylmethyl)amine and Phen = 1,10-phenanthroline) (Figure 3.2). The above-reported 
complex was synthesized and characterized by Fantoni et al., following a rational design 
so that it combines the following characteristics: a) the catalytic stabilizing effect of TPMA 
for effective intercalation to DNA [261-263] and b) the oxidation properties of copper(II) 
phenanthroline for potent DNA scission [263-265]. Since Cu-TPMA-Phen is a metal-
containing chemical that induces DNA cleavage, it may belong to the group of AMNs that 
exert cytotoxic effects against human cancer cells [266, 267]. 
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Figure 3.2: (A) Molecular structure of [Cu(TPMA)(Phen)](ClO4)2 (Cu-TPMA-Phen)], where 
TPMA = tris-(2-pyridylmethyl)amine and Phen = 1,10-phenanthroline), synthesized by Fantoni et 
al., (B) Schematic representation of DNA cleavage by the copper complex. 
 
 
3.3 Effects on cell viability  
3.3.1 Cytotoxicity 
Neuroblastoma cells (NB100) were exposed to different concentrations of the complex Cu-
TPMA-Phen (0.1-30 μΜ) for 24, 48 and 72 h. Cell toxicity of free Cu-TPMA-Phen was 
determined using an MTS cell viability assay. Dose-dependent curves were derived (Figure 
3.3A) and the half maximal effective concentration (EC50) values were calculated (Figure 
3.3C). The EC50 was 4.2 μΜ (R2 = 0.97) after 24 h of continuous incubation with the 
complex. Longer incubation times resulted to slightly lower EC50 values, 3.0 μΜ and 2.8 
μΜ for 48 and 72 h, respectively. Cell viability was also evaluated in a pulse and chase 
experiment, in which NB100 cells were treated for 2 h with various concentrations of Cu-
TPMA-Phen (1-100 μΜ), then washed and incubated with complete medium for 24, 48 
and 72 h (Figure 3.3B). The concentrations effective to reduce cell viability by 50% are 
reported in Figure 3.3C. It should be noted that 2 h of exposure to the complex can be 
enough to ensure a strong cytotoxicity. In fact, the comparison of EC50 calculated for 
continuous and pulse and chase experiments shows only one log difference.  
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Figure 3.3: Cytotoxic effect of Cu-TPMA-Phen on NB100 cells; (A) Cell viability curves for 
NB100 cells continuously exposed to different doses of Cu-TPMA-Phen for 24, 48 and 72 h; (B) 
Cell viability pulse and chase curves of NB100 cells exposed at various doses of Cu-TPMA-Phen 
for 2 h and then incubated in complete medium for 24, 48 and 72 h. Cell viability was measured by 
MTS assay and expressed as a percentage of untreated cells. The results in A and B panels are 
presented as the means ± SD of three independent experiments performed in triplicate; (C) Half 
maximal effective concentration (EC50) values were calculated by non-linear regression with 
standard slop analysis.  
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3.3.2 Evaluation of cell death  
To further study the induced cell death pathway, cytofluorimetric analysis through Annexin 
V/PI double staining of NB100 cells treated with Cu-TPMA-Phen was carried out. This 
analysis indicated that NB100 cells treated for 24 h with 5 μΜ Cu-TPMA-Phen underwent 
apoptotic cell death. Treated and untreated cells were stained with Annexin V-EGFP and 
Propidium Iodide (PI) to differentiate apoptosis versus necrosis. Annexin V-EGFP detects 
the externalization of phosphatidylserine in apoptotic cells, while PI stains necrotic cells. 
After treatment with 5 μΜ Cu-TPMA-Phen for 24 h, 59% of the cell population was in late 
apoptosis (Annexin V+/PI+) and 5% of cells underwent necrotic death (Annexin V−/PI+), 
as depicted in Figure 3.4A. The low number of necrotic cells measured in our experiments 
can represent an advantage for a possible therapeutic use of this complex. In fact, necrosis, 
contrary to apoptosis, causes inflammation that can be responsible for unwanted toxicity 
towards surrounding normal tissue [268]. In parallel, cell morphology was analyzed by 
phase-contrast microscopy on NB100 cells incubated with 5 μΜ Cu-TPMA-Phen for 24 h. 
Treated cells showed typical apoptotic morphological features, as shown in Figure 3.4B. 
Finally, to confirm the apoptotic cell death pathway, the caspase 3/7 activity was assessed 
in NB100 cells treated with 5 and 10 μΜ Cu-TPMA-Phen for 24 h in comparison with 
untreated (control) cells (Figure 3.4C). At both concentrations, caspases 3/7 were strongly 
activated in Cu-TPMA-Phen treated cells, reaching values higher than 300% of that of 
control cells.  
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Figure 3.4: Cytotoxic effect of Cu-TPMA-Phen on NB100 cells; (A) The cell death pathway 
triggered by 5 μΜ Cu-TPMA-Phen was evaluated on NB100 cells after 24 h of treatment by 
AnnexinV/PI staining and flow cytometry analysis. FITC-A channel is used for the detection of 
Annexin V-EGFP fluorescence. PE-A channel is used for the detection of PI fluorescence. 
Representative plots of AnnexinV/PI staining of are shown; apoptotic cells (Q4, AnnexinV+/PI−), 
necrotic cells (Q1, AnnexinV−/PI+) and late-stage apoptotic cells (Q2, AnnexinV+/PI+); (B) 
Morphological analysis of NB100 cells treated with 5 μΜ Cu-TPMA-Phen for 24 h, using phase-
contrast microscopy (400×); (C) Caspase 3/7 activation in NB100 cells exposed to 5 and 10 μΜ 
Cu-TPMA-Phen for 24 h. The expression of activated caspases is reported as a percentage of 
untreated cell values. Means ± S.D. of three independent experiments, each in triplicate, are given. 
Statistical significance was determined by unpaired t-test (**** p < 0.0001). 
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3.3.3 Caspase activation 
Caspases are proteolytic enzymes with an important role in the regulation of apoptosis 
[269]. To further characterize the cell death induced by Cu-TPMA-Phen, the initiator 
caspases -1, -2, -8 and -9 and the executioner caspases -3, -7 were evaluated at different 
time points (2, 4, 8, 16 and 24 h) after Cu-TPMA-Phen treatment. Interestingly, the 
activation of all tested caspases was increased only after 8 h of cell incubation with the 
copper complex compared to untreated cells (Figure 3.5).  
 
Figure 3.5: Caspase activation in NB100 cells treated with 5 μΜ Cu-TPMA-Phen. Caspase-1, -2, 
-8, -9 and -3/7 activation was determined at 2, 4, 8, 16 and 24 h as described in Materials and 
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Methods. Caspase activity is expressed as fold increase to control for caspase-1 and -2, and as 
percentage of control for caspase-8, -9 and -3/-7. Control values were obtained from cultures grown 
in the absence of copper complex. Mean values ± SD are reported. Cell viability was evaluated at 
the same time points. Statistical significance was determined by unpaired t-test (* p < 0.05, ** p < 
0.01, *** p < 0.001, **** p < 0.0001). 
 
In particular, Cu-TPMA-Phen induced a strong activation of all the apical caspases (-1, -2, 
-8 and -9) in a linear manner, reaching about 1600% (for caspase -1, -2) and 440% (for 
caspase -8, -9) of controls after 24 hours of incubation. Caspase -8 and -9 represent the 
initiator caspases for the extrinsic and intrinsic apoptotic pathway, respectively. The 
extrinsic pathway of apoptosis is activated through the binding of a ligand to the membrane 
death receptor which in turn leads the dimerization and activation of caspase-8. The 
intrinsic pathway is activated by various cellular stresses and involves the mitochondrial 
release of cytochrome c and the formation of the apoptosome, which leads to the activation 
of caspase-9 [270].  The activated form of both caspases (-8, -9) cleave and activate in turn 
the executioner caspases, such as caspase -3 and -7 (Figure 3.6). In the present case, Cu-
TPMA-Phen treatment led to notable augmentation of caspase -3/-7 activity compared to 
untreated cells (~2900%). Besides its categorization to the group of apical caspases, 
caspase-2 is not involved in the cleavage and activation of downstream executioner 
caspases.  The activation of caspase-2 has been attributed to diverse stress signals, such as 
DNA damage, metabolic imbalance, endoplasmic reticulum (ER) stress and others [271, 
272].  Caspase -1 is known to be activated by inflammasomes and trigger pyroptosis; a 
process of programmed cell death that involves cell lysis and extracellular release of 
cytosolic contents, thus leading to the activation of an inflammatory cascade [273]. ROS 
have been recently reported as activating signals for inflammasomes, through MAPK-
ERK1/2 pathway [274].  
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Figure 3.6: Molecular pathways of caspases activation in programmed cell death, such as apoptosis 
and pyroptosis. Intrinsic apoptotic pathway is activated by various stress signals and involves 
cytochrome c release from mitochondria and apoptosome formation, thus leading to activation of 
initiator caspase-9. Extrinsic apoptotic pathway is activated by the binding of death ligand to the 
receptor and leads to initiator caspase-8 activation. Activation of effector caspase-3, -6, and -7 
follows. Inflammasome formation induces caspase-1 activation, which leads in pyroptosis. 
 
3.3.4 Protection by inhibitors/scavengers 
Inhibitors of apoptosis, necroptosis and oxidative stress were tested to evaluate their 
protective effect against Cu-TPMA-Phen cytotoxicity. Cell viability was evaluated using 
NB100 cells pretreated for 3h with 100 µM pan-caspase inhibitor Z-VAD, 100 µM 
necrostatin-1 (Nec-1), 1000 U/ml catalase (CAT), 1 mM sodium pyruvate (NaPyr), 1 mM 
N-acetyl-cysteine (NAC) and then treated with 5 and 10μΜ Cu-TPMA-Phen for 24 h. The 
inhibitor Z-VAD exerted a protective role against copper complex’s cytotoxicity since we 
observed almost full recovery of cell viability when cells were pre-treated with it. Similar 
protective effect was observed when cells were treated with the necroptotic inhibitor Nec-
1 (Figure 3.7A). In these experiments, Nec-1 was able to protect NB100 cells from the 
damage induced by the Cu-TPMA-Phen at a similar level as Z-VAD, thus suggesting that 
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both apoptosis and necroptosis are involved in its cytotoxic mechanism. Necroptosis is a 
recently identified programmed cell death and consists a form of regulated necrosis, which 
depends on the receptor-interacting serine-threonine kinase RIPK1 and RIPK3. Nec-1 
inhibits necroptosis through the inhibition of RIPK1 [275]. It has been demonstrated that 
ROS have a highly important role in the process of necroptosis downstream of RIPK1 
activation [276]. Moreover, necroptotic cell death has been associated with the occurrence 
of excessive DNA damage [277]. Catalase, that enzymatically reduces the hydrogen 
peroxide, protects the cell fate. Sodium pyruvate, which is known to have protective effects 
against hydrogen peroxide toxicity in human neuroblastoma cells [278], showed no 
protection in this case. On the other hand, N-acetyl-cysteine (NAC), which 
increases glutathione levels and thus its antioxidant effects [279], protects the cell viability 
(Figure 3.7B). These results suggest that cytotoxicity of copper complex is mediated 
mainly through oxidative stress and subsequent apoptosis and necroptosis in neuroblastoma 
cells. Phase-contrast microscopy was applied for the morphological analysis of NB100 
cells treated under the conditions described above (Figure 3.7C). While 24-h incubation 
with Cu-TPMA-Phen at EC50 doses, induces cellular death and the formation of apoptotic 
bodies, the pre-treatment with inhibitors of apoptosis/necroptosis and scavengers of 
oxidative stress, rescues the cells from the complex’s cytotoxic effects and cell morphology 
remains similar to untreated cells. 
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Figure 3.7: Protective effect against copper complex’s cytotoxicity by inhibitors of apoptosis and 
necroptosis and scavengers of oxidative stress; (A) NB100 cells were pretreated for 3h with 100 
µM pan-caspase inhibitor (Z-VAD), 100 µM necrostatin-1 (Nec-1), ) and then treated with 5 and 
10 μΜ Cu-TPMA-Phen for 24 h; (B) NB100 cells were pretreated for 3h with 1000 U/ml catalase 
(CAT), 1 mM N-acetyl-cysteine (NAC), and then treated with 5 and 10 μΜ Cu-TPMA-Phen for 24 
h; (C) Morphological analysis of NB100 cells treated under the with conditions mentioned above, 
using phase-contrast microscopy (400×). Values represent mean ± SD of three independent 
experiments, each in triplicate. Statistical significance was determined by unpaired t-test (**** p < 
0.0001). 
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3.4 Effects on membrane lipidome 
 
3.4.1 Membrane fatty acid analysis of copper treated cells 
Based on the cytotoxicity parameters identified above, NB100 cells were treated with 5 μΜ 
of Cu-TPMA-Phen for 24 h (N=6) and underwent fatty acid-based membrane lipidomic 
analyses. The fatty acid residues present in membrane phospholipids were isolated, 
derivatized to fatty acid methyl esters (FAME) and analyzed by gas chromatography (GC). 
GC separation led to the identification and quantification of fatty acid isomers. Membrane 
fatty acid-based lipidomics analysis on NB100 after 24-h treatment revealed a significant 
increase of saturated fatty acids (SFA) (p<0.0001) accompanied by a parallel decrease of 
their monounsaturated (MUFA) counterparts (p<0.0001) (Figure 3.8A). The family of 
polyunsaturated fatty acids (PUFA) did not show significant alterations between treated 
and untreated cells. In particular, the main members of the SFA family, palmitic (16:0) and 
stearic (18:0) acids, are significantly increased (Figure 3.8B), whereas the main members 
of the MUFA family, palmitoleic (9c-16:1), vaccenic (11c-18:1) and oleic (9c-18:1) acids 
showed significantly decreased levels in NB100 cells exposed to Cu-TPMA-Phen (Figure 
3.8C). The enzymatic activity of stearoyl-CoA desaturase (SCD1) can be estimated by the 
product-to-precursor fatty acid ratio [241, 242]. SCD1, also named as delta-9 desaturase, 
catalyzes the conversion of saturated fatty acids (palmitic acid 16:0, or stearic acid 18:0) 
into monounsaturated fatty acids (palmitoleic acid 16:1, or oleic acid 18:1). In Cu-TPMA-
Phen treated NB100 cells, the SCD1 activity was 2-fold decreased (p<0.0001) (Figure 
3.8D). The detailed values of the analyzed fatty acid methyl esters (FAME) and the 
corresponding indices are presented later in this chapter in Tables 3.1 and 3.2, respectively. 
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Figure 3.8: Fatty acid-based membrane lipidomics on NB100 cells treated with 5 μΜ free Cu-
TPMA-Phen for 24 h; (A) Relative distribution of fatty acid families, SFA: saturated fatty acids, 
MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids; (B) Palmitic (16:0) and 
stearic (18:0) acids trends in treated cells; (C) Palmitoleic (9c-16:1), vaccenic (11c-18:1) and oleic 
(9c-18:1) patterns in treated cells; (D) Estimation of delta-9 desaturase (des9) activity by the ratio 
palmitoleic/palmitic and oleic/stearic. Values represent mean ± SD (n=6). Statistical significance 
was calculated with unpaired t-test * (p < 0.05), ** (p < 0.01), **** (p < 0.0001). 
 
The membrane lipidomic experiments were carried out also in the breast cancer-derived 
MCF7 cell line. The aim of this was to ascertain that the above-described membrane 
remodeling is not specific for the neuroblastoma cell line NB100 but can be extended to 
other cancer models. MCF7 cells were exposed to 10 μΜ Cu-TPMA-Phen (~ EC50 value) 
and membrane fatty acid analysis followed. Interestingly, Cu- TPMA-Phen showed a 
similar effect on cell membrane for both cell lines, although MCF7 and NB100 are cells of 
different origin, carcinoma, and neuroblastoma, respectively (Figure 3.9).  
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Figure 3.9:  Fatty acid-based membrane lipidomics on MCF7 cells treated with 10 μΜ free Cu-
TPMA-Phen for 24 h; (A) Relative distribution of fatty acid families, SFA: saturated fatty acids, 
MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids; (B) Palmitic (16:0) and 
stearic (18:0) acids trends in treated cells; (C) Palmitoleic (9c-16:1), vaccenic (11c-18:1) and oleic 
(9c-18:1) patterns in treated cells; (D) Estimation of delta-9 desaturase (des9) activity by the ratio 
palmitoleic/palmitic and oleic/stearic. Values represent mean ± SD (n=6). Statistical significance 
was calculated with unpaired t-test * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001). 
 
The results obtained from the cell viability experiments and death pathways analysis 
together with the values obtained from membrane fatty acid-based lipidomics suggested an 
interesting behavior arising from oxidative conditions typically associated with copper 
complex exposure [254, 280]. In fact, cell membranes exposed for 24 h to the free Cu-
TPMA-Phen did not show a diminution of the PUFA residues of phospholipids. Lipid 
peroxidation and the subsequent PUFA decrease is the typical response of cellular 
membranes to such oxidizing molecules [204, 281]. Thus, the expected chemical reactivity 
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of Cu-TPMA-Phen towards lipid molecules was not observed. Instead, the increase of SFA 
was associated with MUFA diminution, which is distinct from oxidative response. Indeed, 
MUFA decrease cannot be induced by oxidation while the PUFA levels remain unchanged. 
Therefore, our hypothesis is that this MUFA diminution may be attributed to a “metabolic” 
rather than a “chemical” oxidative effect of Cu-TPMA-Phen. Since SFA are less 
susceptible to peroxidation, higher saturation degree in membrane contributes to higher 
protection from ROS [282]. Furthermore, the increase of SFA in membrane phospholipids 
is known to change membrane properties toward less permeability and fluidity [23]. Such 
changes can in turn trigger several signals that lead to programmed cell death, as reported 
in the case of supplementation with palmitic acid of NB100 cells [20]. Our interest was 
further focused to get a deeper insight into the reasons of such a membrane remodeling 
upon cell treatment with toxic concentrations of the copper complex (Figure 3.10). SFA 
and MUFA are metabolically connected through the enzyme stearoyl-CoA desaturase 
(SCD1), which is responsible for the insertion of a double bond at C9 position by catalyzing 
the reduction of SFA to MUFA [241].  
 
Figure 3.10: Hypotheses for the molecular base of membrane remodeling upon cell treatment with 
EC50 value of Cu-TPMA-Phen; Hypothesis A: enzymatic inhibition of stearoyl-CoA desaturase 
(SCD1) that catalyzes the conversion of SFA to MUFA; Hypothesis B: Association of membrane 
remodeling with cytotoxic effects of the copper complex and the consequent induction of apoptosis.  
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The inhibition of desaturase is known to induce cancer cell death and is indeed inspiring 
new pharmacological strategies in anticancer therapy [138]. On the other hand, the 
molecular basis of such membrane remodeling could be possibly associated with the 
observed apoptotic fate, since the interplay between cell membrane composition and 
cellular death is well known [178]. 
 
3.4.2 Time-course lipidomics 
To better evaluate the connection between the cytotoxic events and membrane fatty acid 
remodelling, we performed time course membrane lipidomics in copper complex-treated 
cells and correlated these results with the cell viability and caspase activation in a time-
dependent manner. More specifically, NB100 cells were treated with 5 μΜ Cu-TPMA-
Phen for 2, 4, 8, 16 and 24 h. Cells were harvested at these time points and membrane 
lipidomic analysis was carried out. The fatty acid content of treated cells was compared to 
the one obtained from untreated cells at the same incubation periods. The results are 
presented as % difference of control cells. Time-course membrane lipidomics revealed a 
gradual membrane remodelling upon copper complex treatment (Figure 3.11). The relative 
distribution of total SFA increased significantly in Cu-TPMA-Phen treated NB100 cells at 
the time point of 16 h (p<0.0001). However, stearic (18:0) acid was characterized by a 
significant increase after 4 h-treatment (p<0.05). Moreover, the treated cells showed higher 
% difference for stearic than palmitic (16:0) acid. Total MUFA content was significantly 
lower after 8 h-treatment (p<0.05), reaching a 25% decrease after 24 h-treatment 
(p<0.0001). All the members of MUFA family followed the same decreasing trend, thus 
indicating a global alteration pattern. Although not significant, the PUFA were 
characterized by a slightly increasing trend along treatment time. Interestingly, the 
membrane remodeling was observed even at the very early time points, having an evident 
trend after 8 h incubation. Comparison of the time-course lipidomic changes with the 
corresponding curves for cell viability and caspase activation drives to the conclusion that 
membrane remodelling takes place prior to the detected cytotoxic effects of Cu-TPMA-
Phen. Indeed, cell viability at 8 h is still 100% compared to control cells and caspases 
activation is detected only after 8 h-monitoring. 
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Figure 3.11: Time-dependent membrane remodeling in NB100 cell line treated with 5 μΜ Cu-
TPMA-Phen. Values are expressed as % difference to untreated cells and represent mean ± SD, 
(N=3). Statistical significance was calculated with unpaired t-test * (p < 0.05), ** (p < 0.01), *** 
(p < 0.001), **** (p < 0.0001). SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, 
PUFA: polyunsaturated fatty acids. 
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3.4.3 Membrane fatty acid analysis after inhibitors/scavengers pre-treatment 
The observed membrane remodeling could be indirectly caused because of the complex’s 
cytotoxicity since it is well known the interplay between membrane remodeling and cell 
death. To examine a possible connection between the cytotoxic events and fatty acid 
changes, we performed lipidomic analysis in the presence of Cu-TPMA-Phen in cells that 
were pre-treated with apoptosis inhibitor (Z-VAD) and oxidative stress scavengers 
(catalase and N-acetyl-cysteine). Previous results showed that the Z-VAD and the 
scavengers (catalase and NAC) had a protective effect against Cu-TPMA-Phen cytotoxicity 
(Figure 3.7). In these experiments, NB100 cells were pretreated for 3 h with Z-
VAD/catalase/NAC and then incubated for 24 h in the presence of the copper complex at 
the EC50 concentration. Fatty acid analysis revealed that cell viability protection by 
apoptosis inhibitor and catalase prevented the membrane remodeling, which is induced in 
NB100 cell line after Cu-TPMA-Phen treatment. On the contrary, pre-incubation with 
NAC led to significant differences in fatty acid composition in copper complex treated 
cells. In particular, total MUFA were slightly decreased (p<0.05), while PUFA family 
showed a similar decrease (p<0.05). However, the observed differences in membrane 
lipidome were not so profound compared to the changes characterizing the NB100 cells 
incubated with the Cu-TPMA-Phen without any pre-treatment. Furthermore, the different 
effect on fatty acid composition, after cell pre-treatment with NAC, could be attributed to 
the fact that NAC shows slightly lower protection of cell viability compared to Z-VAD and 
CAT (Figure 3.7). The above results lead us to the conclusion that the membrane 
remodeling is possibly correlated to the cytotoxic mechanism of the copper complex. 
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Figure 3.12: Changes of membrane fatty acids after pre-treatment with inhibitor of apoptosis and 
ROS scavengers. NB100 cells were pretreated for 3 h with 100 µM pan-caspase inhibitor (Z-VAD), 
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1000 U/ml catalase (CAT), 1 mM N-acetyl-cysteine (NAC) and then treated with 5 μΜ Cu-TPMA-
Phen for 24 h. Fatty acid-based membrane lipidomics followed for treated and untreated cells. 
Values represent mean ± SD (n=3). Statistical significance was calculated with unpaired t-test * (p 
< 0.05), *** (p < 0.001). 
 
 
3.5 Cell-free SCD1 activity assay 
The plasma membrane remodeling, which took place after cell treatment with Cu-TPMA-
Phen, could suggest a possible inhibition of stearoyl-CoA desaturase (SCD1). Since SFA 
and MUFA are metabolically connected through the SCD1 desaturase, we hypothesized 
that the copper complex could provoke the inhibition of this enzyme. Indeed, within the 
catalytic area of the desaturase, there is a highly conserved histidine-box that coordinates 
with a di-iron center. Thus, the copper of the complex could, in theory, substitute the iron 
in the active site. To test this hypothesis, we developed a cell-free assay to assess the SCD1 
enzymatic activity in the presence of Cu-TPMA-Phen. SCD1 is a transmembrane enzyme, 
located on the endoplasmic reticulum (ER), with its catalytic area towards the cytoplasm. 
For the assay, we isolated microsomes (extracted forms of ER) from NB100 cell line by 
sequential centrifugation and resuspension in 0.1 M potassium phosphate buffer (pH 7.2). 
Protein concentrations were determined by the method of Bradford. The reaction mixture 
for the stearoyl-CoA desaturase activity included the following: 60 μM stearoyl-CoA, 2 
mM NADH in 10 mM potassium phosphate (pH 7.2), 0.1 M potassium phosphate (pH 7.2), 
and 100 μg of microsomal protein in a final volume of 100 μl. Reactions were performed 
at 37 °C for 10 min under shaking. The positive control included all the above-mentioned 
components. As a negative control, this reaction was performed in the presence of the 
commercially available inhibitor of the desaturase, MF-438 (Calbiochem). Finally, another 
reaction including the copper complex was performed. The enzymatic activity was 
estimated by the ratio of oleic (18:1c9) to stearic (18:0), representing the conversion rate 
of the saturated fatty acid to its monounsaturated counterpart [241, 242]. In the presence of 
Cu-TPMA-Phen, it was calculated a ratio of 1.16, which was identical to the control sample 
(ratio 1.18). In the presence of MF-438 inhibitor, the ratio was decreased to 0.72, proving 
the SCD1 enzyme’s inhibition, since less oleic but more stearic were observed at the end 
of the reaction compared to control sample. The above result suggests that the previously 
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noted increase of SFA of Cu-TPMA-Phen-treated cells cannot be attributed to a specific 
inhibition of this desaturase. 
 
Figure 3.13: Cell-free assay for SCD1 activity; (A) Scheme of the enzymatic reaction catalyzed by 
stearoyl-CoA desaturase (SCD1); (B) SCD1 activity was tested in microsomes extracted from 
NB100 cell line in the presence of 5 μΜ Cu-TPMA-Phen. The commercial inhibitor (MF-438) for 
SCD1 was used as a negative control. SCD1 activity was estimated using the product-to-precursor 
fatty acid ratio (oleic/stearic). Values represent mean ± SD (N=3). Statistical significance was 
calculated with unpaired t-test ** (p < 0.01). 
 
 
3.6 Fatty acids supplementation 
Finally, based on the above-mentioned membrane lipidomics results, we were interested to 
test whether a tailored fatty acid supplementation can influence the cell response to Cu-
TPMA-Phen exposure. We used palmitic and oleic acid since the previous membrane 
lipidomics results showed that both fatty acids were significantly changed upon copper 
complex treatment. Fixed concentrations of 50 μΜ palmitic and 100 μΜ oleic acid, which 
are non-toxic doses [20], were used for simultaneous cell treatment with increasing 
concentrations of Cu-TPMA-Phen (0.3-100 μΜ). Cell viability was determined 24 h after 
cell treatment (Figure 3.14). The obtained results suggest that palmitic acid 
supplementation may have an additive, but not synergistic, cytotoxic effect with Cu-
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TPMA-Phen on NB100 cells, since co-treatment results in slightly higher cytotoxicity 
(p=0.0189). In the case of oleic acid supplementation, the cell viabilities curves showed no 
significant difference (p=0.0905). 
 
 
Figure 3.14: Effects of fatty acid supplementation on Cu-TPMA-Phen induced cytotoxicity. 
NB100 cells were exposed to different doses of Cu-TPMA-Phen for 24 h. Culture medium was 
supplemented with either 50 μΜ palmitic acid (PA) or 100 μΜ oleic acid (OL). Cell viability was 
measured by MTS assay and expressed as a percentage of untreated cells. The results are presented 
as the means ± SD of three independent experiments performed in triplicate. Comparison of cell 
viability curves was conducted with F test (sum-of-squares). 
 
Subsequently, we were interested to study the effect of 100 μΜ oleic acid supplementation 
on the fatty acid content of NB100 cells, which were co-treated with 5 μΜ Cu-TPMA-Phen 
(Figure 3.15A). However, in this case we determined the total fatty acid content of the cells, 
which represents not only the membrane phospholipid fatty acid content but also the one 
of triglycerides (TG), that were formed upon oleic acid supplementation as shown by thin 
layer chromatography (TLC) (Figure 3.15B). Interestingly, oleic acid shows higher levels 
in the case of co-treatment compared to its administration alone. A hypothesis could be 
drawn that the increased levels of oleic acid detected in the supplemented cells treated with 
the copper complex could belong mostly to TG, thus not affecting either the membrane 
content and cell viability. 
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Figure 3.15: (A) Saturated and monounsaturated fatty acid analysis of NB100 cells co-treated with 
5 μΜ Cu-TPMA-Phen and 100 μΜ oleic acid. Values represent mean ± SD (N=3); (B) Formation 
of triglycerides as revealed by thin layer chromatography (TLC) when oleic acid is present. Lane 
1: untreated cells, lane 2: 100 μΜ oleic acid, lane 3: 5 μΜ Cu-TPMA-Phen and lane 4: 5 μΜ Cu-
TPMA-Phen plus 100 μΜ oleic acid. CE: cholesteryl esters; CO: cholesterol; PL: phospholipids; 
TG: triglycerides. 
 
 
3.7 Drug encapsulation in pH-sensitive polymeric nanoparticles 
 
3.7.1 Cytotoxicity of encapsulated Cu-TPMA-Phen 
Cell viability assays were performed to assess the toxicity effect of Cu-TPMA-Phen when 
the latter is encapsulated in pH-sensitive nanocarriers. The encapsulation of this complex 
in nanocontainers was carried out as described in by Toniolo et al. (2018). The resulting 
viability curves were compared to those obtained after treatment with free Cu-TPMA-Phen 
in the same concentration range, 0.1-30 μΜ, as shown in Figure 3.16A. Incubation with 3, 
10 and 30 μΜ Cu-TPMA-Phen for 24 h results in significantly different viability between 
cells treated with free and encapsulated complex (p< 0.0001, 3 and 10 μΜ and p< 0.01, 30 
μΜ).  Analogous experiments were carried out for 48 h, resulting also in significant 
changes between the free and encapsulated form of the complex (Figure 3.16B). However, 
it should be considered that these differences do not indicate a lower activity of the NCs 
because the maximum release is at pH 4.0, which is a condition easily obtainable in cancer 
The copper complex: Cu-TPMA-Phen 
 
68 
 
microenvironment, but quite far from cell culture conditions. These differences in 
cytotoxicity can be attributed to the less amount of bioavailable drug. In fact, as described 
by Toniolo et al., only 1/3 of Cu-TPMA-Phen is released from nanocontainers at the 
physiologic pH 7.4, which is similar to cell culture conditions. 
 
 
Figure 3.16: Dose-dependent response of NB100 cells treated with free or encapsulated Cu-TPMA-
Phen for 24 and 48 h, panel A, and B, respectively. Cell viability was estimated with MTS assay. 
The results are presented as the means ± S.D. of three independent experiments performed in 
triplicate, representing the percentage of control values obtained from cultures grown in the absence 
of the complex. Statistical analysis was performed with unpaired t-test ** (p < 0.01), **** (p < 
0.0001). 
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3.7.2 Membrane lipidomics of encapsulated Cu-TPMA-Phen 
Membrane lipidomics analysis was also performed on NB100 cells treated with 5 μΜ of 
encapsulated Cu-TPMA-Phen in pH-sensitive nanocarriers. In this case, the impact on 
membrane lipidome presents no significant differences between untreated and treated cells 
(Figure 3.14A, B, C, D). 
 
 
Figure 3.17: Fatty acid-based membrane lipidomics on NB100 cells treated with 5 μΜ 
encapsulated Cu-TPMA-Phen for 24 h; (A) Relative distribution of fatty acid families, SFA: 
saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids; (B) 
Palmitic (16:0) and stearic (18:0) acids trends in treated cells; (C) Palmitoleic (9c-16:1), vaccenic 
(11c-18:1) and oleic (9c-18:1) patterns in treated cells; (D) Estimation of delta-9 desaturase (des9) 
activity by the ratio palmitoleic/palmitic and oleic/stearic. Values represent mean ± SD (n=6). 
Statistical significance was calculated with the unpaired t-test. des9: Δ9-desaturase activity. 
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In this work, we observed the absence of effects of the copper complex when encapsulated 
in pH-sensitive nanocarriers, which do not release sufficient drug doses for membrane 
remodeling, but also suggests further studies on the control of oxidative effects by drug 
delivery in sense of enhanced tumor targeting [283]. In Tables 3.1 and 3.2, the detailed 
values of the analyzed fatty acids and their indices are presented, respectively. 
 
Table 3.1: Relative percentages (% rel) and indices of membrane fatty acids methyl esters (FAME) 
of NB100 cells treated with 5 μΜ free or encapsulated Cu-TPMA-Phen. P-value represents the 
comparison among all the groups after conducting one-way ANOVA test. Stars indicate the 
statistically significant difference (Dunnett's multiple comparison test) between each treated group 
and the control cells (n=6); * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001). 
FAME Control 
Free 
Cu-TPMA-Phen 
Encapsulated 
Cu-TPMA-Phen 
p-value 
SFA 
16:0 20.43 ± 1.28 22.86 ± 2.21* 20.54 ± 0.78 0.0412 
18:0 10.85 ± 1.64 20.05 ± 1.71**** 11.45 ± 1.42 < 0.0001 
20:0 0.27 ± 0.20 0.46 ± 0.04* 0.19 ± 0.02 0.0060 
MUFA 
16:1c6 1.52 ± 0.09 1.32 ± 0.10** 1.47 ± 0.07 0.0065 
16:1c9 5.54 ± 1.05 3.72 ± 0.73** 5.08 ± 0.81 0.0133 
18:1c9 37.17 ± 1.52 28.13 ± 0.99**** 36.80 ± 1.20 < 0.0001 
18:1c11 9.62 ± 1.34 7.10 ± 0.92** 9.35 ± 1.52 0.0138 
20:1c11 1.29 ± 0.29 0.94 ± 0.20 1.35 ± 0.32 0.0700 
PUFA ω6 
18:2 2.20 ± 0.23 2.40 ± 0.43 2.29 ± 0.34 0.6369 
20:2 0.39 ± 0.06 0.43 ± 0.08 0.40 ± 0.07 0.5248 
20:3 0.58 ± 0.06 0.81 ± 0.12** 0.61 ± 0.08 0.0021 
20:4 4.06 ± 0.73 4.51 ± 1.08 4.13 ± 0.78 0.6950 
PUFA ω3 
18:3 0.09 ± 0.02 0.12 ± 0.03 0.09 ± 0.02 0.0840 
20:5 0.81 ± 0.20 0.99 ± 0.26 0.85 ± 0.17 0.3822 
22:5 1.94 ± 0.12 2.22 ± 0.22* 2.01 ± 0.16 0.0485 
22:6 2.23 ± 0.64 2.78 ± 0.83 2.35 ± 0.63 0.4525 
Total trans 
18:1 0.63 ± 0.10 0.66 ± 0.06 0.64 ± 0.06 0.8524 
18:2 0.22 ± 0.04 0.25 ± 0.04 0.22 ± 0.04 0.5132 
20:4 0.16 ± 0.04 0.23 ± 0.06* 0.17 ± 0.02 0.0583 
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Table 3.2: Indices of membrane fatty acids methyl esters (FAME) of NB100 cells treated with 5 
μΜ free or encapsulated Cu-TPMA-Phen. P-value represents the comparison among all the groups 
after conducting one-way ANOVA test. Stars indicate the statistically significant difference 
(Dunnett's multiple comparison test) between each treated group and the control cells (n=6); * (p < 
0.05), ** (p < 0.01), **** (p < 0.0001). des9: Δ9-desaturase activity. 
Index Control 
Free 
Cu-TPMA-Phen 
Encapsulated 
Cu-TPMA-Phen 
p-value 
SFA 31.55 ± 2.48 43.38 ± 0.92**** 32.17 ± 1.82 < 0.0001 
MUFA 55.14 ± 4.05 41.22 ± 2.60**** 54.05 ± 3.71 < 0.0001 
PUFA 12.29 ± 1.99 14.27 ± 2.94 12.74 ± 2.18 0.4137 
PUFA ω6 7.22 ± 1.06 8.16 ± 1.72 7.43 ± 1.26 0.5408 
PUFA ω3 5.07 ± 0.94 6.12 ± 1.24 5.31 ± 0.92 0.2789 
SFA/MUFA 0.58 ± 0.08 1.06 ± 0.06**** 0.60 ± 0.07 < 0.0001 
ω6/ω3 1.44 ± 0.07 1.33 ± 0.05* 1.40 ± 0.03 0.0219 
total trans 1.01 ± 0.13 1.13 ± 0.13 1.04 ± 0.10 0.2812 
des9 (16:1/16:0) 0.27 ± 0.07 0.16 ± 0.02** 0.25 ± 0.04 0.0062 
des9 (18:1/18:0) 3.54 ± 0.77 1.42 ± 0.17**** 3.28 ± 0.53 < 0.0001 
 
 
3.8 Conclusions 
In the present research project, the novel Cu(II) complex [Cu(TPMA)(Phen)](ClO4)2 was 
studied being used both as a free compound and under an encapsulated form within 
polymeric nanoparticles, thus allowing for the comparison with the free drug. In vitro 
experiments were carried out in the neuroblastoma derived cell line NB100 cell line and 
breast carcinoma cell line MCF7. The cytotoxicity of both free and encapsulated complex 
was determined and the cell death pathways were analyzed with parallel monitoring of 
caspase activation. Inhibitors of apoptosis, necroptosis and scavengers of oxidative stress 
were tested to evaluate their protective effect against copper’s cytotoxicity. NB100 cells 
were treated with EC50 doses of copper complex and membrane fatty acids were isolated, 
derivatized and analyzed by gas chromatography. As expected, membrane remodeling took 
place upon treatment with the copper complex prior to cell viability decrease. The observed 
changes in fatty acid composition included significant increase of SFA and diminution of 
MUFA, while PUFA levels did not alter. Since, SFA and MUFA are metabolically 
connected through the SCD1 desaturase activity, we hypothesized that the copper complex 
could provoke the inhibition of this enzyme. To test this hypothesis, we developed a cell-
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free assay to assess the SCD1 enzymatic activity in the presence of copper complex. On 
the other hand, the observed membrane remodelling could be indirectly caused because of 
complex’s cytotoxicity since it is well known the interplay between membrane remodelling 
and cell death. To examine a possible connection between the cytotoxic events and fatty 
acid changes, we performed lipidomic analysis in the presence of complex in cells that 
were pre-treated with apoptosis inhibitor and ROS scavengers. To further study this 
phenomenon, we performed time course lipidomics in complex-treated cells and correlated 
these results with the cell viability and caspase activation at the same time points. Finally, 
we were interested to test whether a tailored fatty acid supplementation could influence the 
cell response to copper complex exposure. 
The main results include: i) oxidative stress-mediated cytotoxicity of copper complex and 
subsequent apoptosis and necroptosis in neuroblastoma cells, ii) membrane remodeling of 
treated cells with a specific increase of saturated fatty acids (SFA) and a decrease of 
MUFA, but not PUFA in both NB100 and MCF7 cell lines; iii) possible correlation of 
membrane remodeling with the cytotoxic mechanism of the copper complex, iv) 
elimination of the drug’s effects on cell viability and membrane lipidome when Cu-TPMA-
Phen is encapsulated in pH-sensitive polymeric nanoparticles, due to drug’s delayed release 
and reduced bioavailability.  
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4. Membrane remodeling in tumor-bearing mice models 
4.1 Background and Objectives  
The project described in the present chapter was performed in collaboration with the group 
of Dr. E. Efthimiadou at the Institute of Nanoscience and Nanotechnology, N.C.S.R. 
“Demokritos”. The overall goals of this research project were to a) evaluate the erythrocyte 
membrane fatty acid remodeling in normal and tumor-bearing mice at different stages of 
tumor occurrence and b) study the erythrocyte membrane fatty acid composition in normal 
and tumor-bearing mice, after administration of iron oxide nanoparticles and bleomycin. 
The mice models here studied were constructed, hosted and treated by our collaborators at 
the NCSR “Demokritos”. Whole blood was collected in EDTA-treated tubes and shipped 
within 2 days in the laboratory of the CNR/spin-off company Lipinutragen where the 
erythrocyte membrane fatty acid analysis was carried out. 
Lipid metabolic reprogramming is an established hallmark of cancer development [96], 
which among others includes a distinct fatty acid biosynthesis due to the rapid proliferation 
of cancer cells [103, 105]. Indeed, key enzymes that are involved in lipid biosynthesis, such 
as fatty acid synthase (FASN) and desaturases (SCD1, D5D, D6D), show increased activity 
in tumor development and propagation. These elevated enzymatic activities along with the 
corresponding fatty acids are thus pointed as markers of tumor presence and growth [42, 
72, 105, 106]. It is well known that the fatty acid composition of the cellular membrane 
affects its fluidity, permeability as well as membrane lipid-related signaling. Alterations to 
the fatty acid content and consequently to the membrane properties might give favorable 
signals for tumor growth, progression and metastasis [72, 142, 284]. The membrane 
remodeling is highly affected by the intracellular lipid pool, which in turn depends on both 
the endogenous fatty acid biosynthesis and their dietary intake, especially in the case of the 
essential polyunsaturated fatty acids (PUFA) [285]. Several independent studies have 
revealed apparent correlations between the erythrocyte membrane phospholipid fatty acid 
concentrations and tumor risk [157, 158, 161-163]. Furthermore, differences on the fatty 
acid composition of tumor colorectal tissues has been reported between patients with and 
without metastasis, suggesting that membrane lipid remodeling could affect the cellular 
function and influence tumor cell metastasis [175]. 
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One of the first discovered antitumoral drugs known to react with the membrane lipids was 
bleomycin (BLM) [199-201]. Bleomycin is a widely known antineoplastic agent, used to 
treat Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular, ovarian, head 
and cervical cancer among others [202]. Its therapeutic use is based, alike the famous 
cisplatin chemotherapy, on its ability to cleave DNA [202, 203]. Inhibition of DNA, RNA 
and protein synthesis by bleomycin has also been reported [203]. Studies have proved that 
DNA strand breaks induced by bleomycin rely on oxygen and metal ions. More 
specifically, it has been suggested that bleomycin chelates metal ions (mainly iron), 
producing a pseudoenzyme that reacts with oxygen to produce superoxide and 
hydroxide free radicals, as shown in Figure 4.1 [286, 287]. Its abilities to chelate redox-
active metal-centers (i.e. Fe(III) or Cu(II)) as well as binding to DNA, enable metallo-
bleomycin to the artificial metallo-nucleases (AMN) category [202]. Moreover, such 
metallo-antibiotics mediate oxidation of other cellular molecules, such as lipid 
peroxidation [204, 205]. 
 
 
Figure 4.1: The free radical pathway generated by iron-bleomycin complex induces DNA and lipid 
damage. 
 
Iron oxide nanoparticles find several medical applications, such as in the field of 
diagnostics (e.g. Magnetic Resonance Imaging - MRI) and therapeutics (e.g. hyperthermia-
based cancer treatment) [288]. They may also serve as drug carriers for specific drug 
delivery, as well as nano-adjuvant for vaccine and antibody production [289]. Despite their 
low toxicity, iron nanoparticles can be degraded in vivo, thus leading to increased iron 
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levels in tissues [290]. The biodistribution of these biodegradation-produced iron ions can 
be then regulated by either ferritin or transferrin, which are the two main iron–binding 
proteins [291, 292]. High levels of intracellular iron have been implicated in the iron-
induced lipid peroxidation, since the free iron ions can react with superoxide or hydrogen 
peroxide to form hydroxyl radicals [293]. 
In the present project, we used a mouse xenograft model, consisting of a severe combined 
immunodeficient (SCID) female mouse, inoculated with the human glioblastoma U87MG 
cell line. Fatty acid composition of erythrocyte membrane was monitored: a) at different 
stages of tumor occurrence and b) at early points of tumor occurrence after administration 
of iron nanoparticles, bleomycin or combination of the latter two. Non-xenografted SCID 
mice that underwent the same treatment with the xenografted ones served as the control 
sample. In parallel, healthy Swiss mice were used for comparison with the tumor-bearing 
SCID mice. 
 
 
4.2 Erythrocyte membrane fatty acid analysis 
4.2.1 Healthy Swiss vs control SCID mice 
Comparison of healthy Swiss and control SCID mice was performed to evaluate the impact 
of the immunodeficiency to the obtained results, later presented in this chapter. Although 
it was not among the main aims to deepen into the differences between these two mice 
models, an initial evaluation of the distribution of the RBC membrane fatty acid families 
in these two animal models was carried out, prior to the examination of the membrane fatty 
acid distribution during the tumor progression in the immuno-deficient model of SCID 
mice. To our knowledge, the erythrocyte membrane fatty acid composition of SCID mice 
has not been evaluated before. For this reason, we performed an initial RBC fatty acid 
analysis aiming at a) the monitoring of fatty acid composition during ageing in both control 
SCID and normal Swiss mice and b) the comparison between these two animal models. 
The % relative distributions of the analyzed fatty acid moieties are reported in Table 4.1. 
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Table 4.1: Relative percentages (% rel) of fatty acids methyl esters (FAME) from red blood cell 
(RBC) membrane of normal healthy Swiss mice and control SCID mice at different age points (4 
weeks and 17 weeks). P-value represents the comparison between young (4 weeks) and old (17 
weeks) mice of each group after conducting unpaired t-test (n=3 for normal Swiss and n=2 for 
SCID mice). 
FAME 
Normal 
Swiss-4w 
Normal 
Swiss-17w 
p-value 
Control 
SCID-4w 
Control 
SCID-17w 
p-value 
SFA 
14:0 0.09 ± 0.13 0.61 ± 0.18 0.3270 0.57 ± 0.06 0.55 ± 0.14 0.9075 
15:0 0.75 ± 0.36 0.56 ± 0.24 0.9054 0.15 ± 0.04 0.15 ± 0.02 >0.9999 
16:0 28.63 ± 0.75 28.38 ± 0.80 0.9994 35.38 ± 0.46 31.78 ± 0.55 0.0377 
17:0 0.29 ± 0.21 0.43 ± 0.10 >0.9999 0.17 ± 0.00 0.16 ± 0.02 >0.9999 
18:0 13.15 ± 0.58 10.57 ± 1.01 0.2690 10.73 ± 0.09 12.11 ± 0.47 0.1022 
MUFA 
16:1c6 0.57 ± 0.15 0.27 ± 0.02 0.0713 0.23 ± 0.02 0.23 ± 0.05 >0.9999 
16:1c9 1.82 ± 0.66 3.09 ± 0.55 0.2269 1.66 ± 0.36 2.89 ± 0.38 0.1426 
18:1c9 15.03 ± 0.96 18.06 ± 1.66 0.4361 15.87 ± 0.95 19.09 ± 1.20 0.1701 
18:1c11 2.67 ± 0.08 3.26 ± 0.03 0.0012 2.70 ± 0.06 2.46 ± 0.07 0.1213 
20:1c11 0.54 ± 0.12 0.39 ± 0.02 0.2181 0.48 ± 0.02 0.39 ± 0.04 0.1425 
PUFA ω6 
18:2 10.63 ± 0.32 12.27 ± 1.28 0.6759 11.22 ± 0.30 11.67 ± 0.25 0.3683 
18:3 0.10 ± 0.14 0.16 ± 0.04 0.9999 0.05 ± 0.05 0.16 ± 0.02 0.1462 
20:2 0.59 ± 0.09 0.39 ± 0.04 0.2793 0.55 ± 0.02 0.39 ± 0.07 0.1386 
20:3 1.44 ± 0.18 1.35 ± 0.05 0.8947 1.22 ± 0.01 1.14 ± 0.13 0.5880 
20:4 14.50 ± 1.07 13.34 ± 1.51 0.9082 11.53 ± 0.99 10.40 ± 0.95 0.4968 
PUFA ω3 
18:3 0.25 ± 0.20 0.24 ± 0.07 0.9286 0.18 ± 0.04 0.18 ± 0.00 0.8995 
20:5 0.63 ± 0.04 0.52 ± 0.14 0.7063 0.43 ± 0.03 0.42 ± 0.03 0.9098 
22:5 0.82 ± 0.15 0.70 ± 0.11 0.8803 0.89 ± 0.05 0.67 ± 0.04 0.0663 
22:6 6.46 ± 0.30 5.35 ± 0.48 0.2110 5.70 ± 0.08 4.84 ± 0.30 0.1091 
trans 
18:1 0.22 ± 0.31 nd 0.6568 nd nd - 
18:2 0.26 ± 0.37 nd 0.6611 0.10 ± 0.00 0.10 ± 0.01 0.6985 
20:4 0.56 ± 0.41 0.20 ± 0.04 0.5000 0.20 ± 0.03 0.24 ± 0.04 0.6513 
 
The comparison between young (4 weeks) and old (17 weeks) mice of each model showed 
no significant difference on the RBC membrane fatty acid composition during ageing. A 
significant change found concerns the 17-weeks old control SCID mice, whose palmitic 
acid (16:0) was slightly decreased (p=0.0377) in contrast to the 4-weeks old SCID mice. 
Despite this diminution of palmitic acid, the fatty acid families and indexes were not 
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influenced. Furthermore, 17-weeks old Swiss mice have higher levels of vaccenic acid 
(18:1c11) opposite to the young ones (p=0.0012). Based on the few alterations detected, 
we consider that the ageing process is not the main factor for potential changes on 
membrane lipidome in the present case. As already mentioned, it was not the scope of this 
project to detail the differences between healthy Swiss and control SCID mice, however 
some interesting information was obtained related to the immunodeficient phenotype. The 
examined mice models (control SCID and healthy Swiss) are characterized by different 
erythrocyte membrane fatty acid profiles. Palmitic (16:0), stearic (18:0) and arachidonic 
(20:4ω6) are among the fatty acids with the most notable variation among the two models 
(Table 4.1), thus affecting the total SFA and PUFA values (Table 4.2). These differences 
could indicate that the immunodeficient phenotype may contribute to the final erythrocyte 
membrane remodeling. For following comparisons, the fatty acid families and indices that 
characterize normal healthy Swiss and control SCID mice at different age points (4- and 
17-weeks old) are presented in Table 4.2. 
 
Table 4.2: Relative percentages (% rel) of fatty acid methyl esters (FAME) families and indices of 
normal healthy Swiss and control SCID mice at different age points (4 weeks and 17 weeks). P-
value represents the comparison between young (4-weeks) and old (17-weeks) mice of each group 
after conducting unpaired t-test (n=3 for normal Swiss and n=2 for control SCID mice). SFA: 
saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; UI: 
unsaturation index; PI: peroxidation index. 
 
Normal 
Swiss-4w 
Normal 
Swiss-17w 
p-value 
Control 
SCID-4w 
Control 
SCID-17w 
p-value 
SFA 42.91 ± 1.41 40.55 ± 1.69 0.3594 46.99±0.35 44.75±0.93 0.1529 
MUFA 20.63 ± 1.49 25.07 ± 2.18 0.3192 20.94±1.20 25.06±1.60 0.1756 
PUFA 35.42 ± 1.15 34.18 ± 0.69 0.9623 32.07±0.85 30.00±0.48 0.1685 
PUFA ω-6 27.26 ± 0.97 27.46 ± 0.42 >0.9999 24.86±0.65 23.89±0.77 0.4339 
PUFA ω-3 8.17 ± 0.21 6.73 ± 0.53 0.1602 7.21±0.20 6.11±0.29 0.0891 
ω-6/ω-3  3.34 ± 0.07 4.11 ± 0.32 0.6196 3.45±0.01 3.93±0.31 0.2671 
SFA/MUFA 2.10 ± 0.22 1.64 ± 0.21 0.7962 2.25±0.15 1.80±0.15 0.1625 
total trans 1.56 ± 0.05 0.20 ± 0.04 0.0006 0.30±0.03 0.34±0.05 0.5636 
UI 152.47 ± 5.58 146.79 ± 4.57 0.8856 135.06±3.01 128.63±0.47 0.1692 
PI 133.73 ± 5.94 119.99 ± 8.77 0.5387 114.39±4.76 101.76±1.50 0.1268 
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4.2.2 Tumor-bearing mice at different stages 
We used an experimental animal model, which was the severe combined immunodeficient 
(SCID) mouse xenografted with a human tumor cell line (glioblastoma U87MG). Such 
human xenografts are widely used in clinical research for the assessment of anticancer 
therapeutics [294, 295]. The diseased model was followed up at different ages (4-, 5- and 
17-weeks old) and was compared with no tumor-diseased SCID mice. Particularly, the 
erythrocyte membrane fatty acid profiles of these animals were monitored at different ages 
in order to track potential RBC membrane profile changes that could mirror the fatty acid 
remodeling and metabolism. 
The flowchart of the protocol used in this study is described in Figure 4.2. Human tumor 
xenograft was obtained by inoculating U87MG human brain glioblastoma cells 
subcutaneously in two weeks old SCID mice. Approximately 2 weeks post-injection, the 
first set of animals was sacrificed (group 3, four-weeks-old). The second set of tumor-
bearing mice was sacrificed one week later (group 4, five-weeks-old) and the third set after 
84 days (group 5, seventeen-weeks old). The group 3 and 4 are referred as the early stage 
of tumorigenesis hereinafter, while the group 5 as the final stage of tumor presence when 
all tumor-bearing mice are characterized by very poor conditions. In parallel, we evaluated 
the fatty acid content of membrane phospholipids in control SCID mice without tumor 
implantation, four-weeks-old (group 1) and seventeen-weeks old (group 2), to identify 
potential differences with tumor-bearing animals. Since in the present study human 
xenograft are selected and tumors originate by exogenously inoculation with human cancer 
cells, tumor tissues were not analyzed, following an approach described for a genetically 
engineered mouse [295]. The fatty acid-based membrane lipidomic study was performed 
using membrane phospholipids isolated from red blood cells (RBCs) with published 
procedures [296]. As shown in Figure 4.2, the extracted RBC phospholipids were 
transformed into fatty acid methyl esters (FAME) under known conditions [297]. FAMEs 
were analyzed by gas chromatography (GC) in order to identify saturated (SFA) and 
unsaturated (MUFA and PUFA) fatty acids, the latter being recognized as positional and 
geometrical isomers [246].  
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Figure 4.2: Flowchart for the analysis and quantification of membrane fatty acid moieties in 
erythrocytes of control SCID mice; group 1: 4-weeks old; group 2: 17-weeks old; and tumor-
bearing SCID mice; group 3: 4-weeks old; group 4: 5-weeks old; group 5: 17-weeks old. 
 
After better understanding the present experimental model (described in section 4.2.1), we 
proceeded with the membrane lipidomic analyses in tumor-bearing mice at an early stage 
of tumorigenesis (4- and 5-weeks old mice) and at a final stage of tumor progression (17-
weeks old tumor-bearing mice). In the present study, the erythrocyte membrane was 
utilized for the examination of fatty acid composition, since it is an easily withdrawn 
biological specimen. Red blood cells are increasingly gaining attention as an interorgan 
communication system, since their crosstalk with other tissues has been revealed [298, 
299]. RBCs structure and function are affected by the presence of ROS, but they also 
participate in the control of redox regulation [91, 299-301]. Recent works suggest that the 
RBC, as a “circulating” cell that is sensing the microenvironment found in all tissues, could 
be considered as a “reporter cell” for the antioxidant status of the other tissues [302-304]. 
Indeed, it has been reported that erythrocyte and liver cells have similar membrane fatty 
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acid composition [305] and mean lifetime (120 and 180 days, respectively). Thus, the fatty-
acid based membrane lipidomics of erythrocytes can serve as a useful tool for the 
extrapolation of information, especially when combined with other relevant metabolic and 
cellular assays [306].  
In Table 4.3, the fatty acids are grouped into families of SFA, MUFA and PUFA 
(graphically represented in Figure 4.3A), trans fatty acids (TFA) (graphically represented 
in Figure 4.3B), as well as into PUFA ω-3, PUFA ω-6 and their ratio. In Table 4.3 the 
calculated indices of unsaturation (UI) and peroxidation (PI) are also reported [246, 307]. 
 
Table 4.3: Relative percentages (% rel) of fatty acid families and indices of erythrocytes obtained 
from control SCID mice (4 weeks and 17 weeks) and tumor-bearing mice at different age points (4 
weeks, 5 weeks and 17 weeks). P-value represents the comparison among all the groups after 
conducting a one-way ANOVA test among all the groups (n=3). 
 
Control 
SCID-4w 
Control 
SCID-17w 
Tumor 
SCID-4w 
Tumor 
SCID-5w 
Tumor 
SCID-17w 
p-value 
SFA 46.99±0.35 44.75±0.93 42.16±0.03 42.54±1.07 57.86±0.44 <0.0001 
MUFA 20.94±1.20 25.06±1.60 20.08±0.08 19.53±0.77 15.54±3.34 0.0658 
PUFA 32.07±0.85 30.00±0.48 37.09±0.13 36.58±0.01 26.60±3.58 0.0190 
PUFA ω-6 24.86±0.65 23.89±0.77 28.56±0.04 27.48±0.04 21.21±3.47 0.0960 
PUFA ω-3 7.21±0.20 6.11±0.29 8.54±0.09 9.11±0.03 5.39±0.94 0.0054 
ω-6/ω-3 3.45±0.01 3.93±0.31 3.35±0.03 3.02±0.01 4.05±1.02 0.5875 
SFA/MUFA 2.25±0.15 1.80±0.15 2.10±0.01 2.18±0.14 3.89±0.76 0.0281 
Total trans 0.30±0.03 0.34±0.05 0.55±0.11 1.36±0.32 0.32±0.07 0.0074 
UI 135.06±3.01 128.63±0.47 159.61±0.53 156.82±0.63 109.00±10.19 0.0014 
PI 114.39±4.76 101.76±1.50 142.52±0.60 140.68±0.24 92.10±13.59 0.0053 
 
The following differences emerged from the comparison between control and tumor-
bearing SCID mice at different time points: 
i. Erythrocyte membrane lipidome profiles showed increased levels of SFA during 
tumor propagation. In particular, the relative percentage of SFA reached ca 58% 
over the total fatty acid composition in late-stage tumor-bearing mice, which is the 
highest SFA percentage found compared to both control SCID and early-stage 
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tumor-bearing mice (ca 42%, p<0.0001). As shown in Table 4.4, all the members 
of the SFA family follow this increasing trend in late-stage diseased SCID mice. 
On the contrary, the fatty acid moieties of MUFA family were decreased in the 
same animals, however not significantly. Consequently, the ratio of SFA/MUFA 
was increased at the erythrocytes of late-stage tumor mice, while the same ratio was 
decreased in the corresponding control SCID mice (p=0.028). 
 
ii. In addition to the above membrane remodeling, PUFA levels were significantly 
decreased in 17-weeks old tumor-bearing SCID mice (p=0.0019). Late stage 
diseased mice were characterized by smaller PUFA content in RCB membrane 
phospholipids compared to the young (4- and 5-weeks old) tumor-bearing age mice 
(p=0.0071 and p=0.0085, respectively). Notably, the PUFA levels in 4-weeks old 
control SCID mice were found much lower compared to corresponding tumor-
bearing and they were even fewer in 17-weeks old control mice, not significantly 
though. Both the families of omega-6 and omega-3 PUFA showed a decreasing 
pattern for late-stage tumor mice, without alterations at their in-between ratio 
(ω6/ω3).  
 
iii. ARA and DHA (members of the ω-6 and ω-3 PUFA families, respectively) show 
also significant depletion in tumor-bearing SCID mice after 17-weeks disease 
progression (p=0.0333 and p=0.0027, respectively), as represented in Figures 4.3D 
and 4.3E. Remarkably, in all cases, the PUFA changes did not involve the ω-6 
precursor linoleic acid (LA: 9cis, 12cis-C18:2), showing only a decreasing trend at 
the late-stage tumor-bearing mice (Tables 4.1 and 4.4 for control and tumor-bearing 
SCID mice, respectively). 
 
iv. The indexes of unsaturation and peroxidizability are significantly decreased (UI and 
PI; p=0.0014 and p=0.0053, respectively) (Table 4.3). It is worth mentioning that 
the neither in SCID mice nor in healthy Swiss mice the UI and PI indexes were 
found significantly affected by the age (Table 4.1).  
 
v. The level of TFA show also an interesting trend for tumor-bearing SCID mice, as 
they increase significantly in 5-weeks old tumor-bearing mice and then they 
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decrease again in 17-weeks old ones (p=0.0074) (Table 4.3 and Fig. 4.3B). No 
significant changes were revealed regarding the control SCID mice.   
 
 
 
Figure 4.3: (A) Fatty acid composition grouped into families SFA, MUFA and PUFA of 
erythrocyte membrane at early and late stage of control SCID and tumour-bearing mice; 
comparison among control (4 weeks and 17 weeks old; group 1 and group 2, respectively) and 
diseased mice (4 weeks old, 5 weeks old and 17 weeks old; group 3, group 4 and group 5, 
respectively); (B) Total trans fatty acids isomers of erythrocyte membrane among control SCID 
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(group 1 and group 2) and tumour-bearing mice (group 3, group 4 and group 5); (C) LH (18:2 ω-
6) levels for the five distinct mice groups; (D) ARA (20:4 ω-6) levels for the five distinct mice 
groups; (E) DHA (22:6 ω-3) levels for the five distinct mice groups. Values represent mean ± SD 
(n=3). * (p< 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001). 
 
As far as the comparison between tumor diseased and healthy Swiss mice is concerned, we 
observed the following: 
i. 4-weeks old tumor-bearing mice showed an erythrocyte membrane lipidomic 
profile quite similar to the one characterizing the healthy Swiss mice at early age 
points (comparison between Table 4.3 with Table 4.2, respectively). The relative 
distribution of fatty acid families (SFA, MUFA and PUFA) was rather comparable 
in the RBC membrane obtained from young mice of both models.  
 
ii. The UI and PI indexes of 4-weeks old diseased SCID mice were more comparable 
to the ones of Swiss healthy than to those of control SCID mice (Tables 4.3 and 
4.2).  
 
iii. The total TFA were decreased during aging only in the case of healthy Swiss mice 
(p=0.0006, Table 4.2). 
 
During tumor progression, the levels of erythrocyte membrane SFA increase, indicating 
their availability from the de novo fatty acid biosynthesis machinery. Indeed, many studies 
report an enhanced fatty acid synthase (FASN) activity in tumor progression [308-311], 
accompanied by an increase of desaturase activity [142], although this latter process was 
not observed in our animal model. In late stage tumor-bearing SCID mice, the SFA increase 
is accompanied by a diminution of PUFA, which are essential or semi-essential molecules 
and are not produced by endogenous biosynthetic pathways. The variation in PUFA levels 
among the different SCID mice (group 1 vs 3 and group 3 vs 5) is interesting, since there 
are numerous original publications and literature reviews discussing the role of PUFA in 
cancer risk [312] and tumor progression [313]. According to the above results, we could 
consider a significant distinction of PUFA levels during tumor progression; increased at 
early stages in tumor-bearing SCID mice and then lowered as the tumor progresses (Table 
4.3). This PUFA diminution could be probably attributed to  lipid peroxidation in cell 
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membranes [104, 314], since tumor tissue is characterized by enhanced oxidative stress 
[315]. ARA (20:4-ω6) and DHA (22:6-ω3), which are the major long chain PUFA 
counterparts in the membrane, are prone to oxidation and showed a significant decrease in 
late-stage tumor-bearing mice. However, it is notable that the levels of LA, which is the ω-
6 precursor, were not significantly altered (Table 4.4). Thus, the hypothesis that oxidative 
processes are localized to tissues rich in ARA and DHA, which are more oxidizable 
molecules, can be fostered. PUFA play also an important role in lipid signaling. For 
instance, the arachidonic acid moieties are removed from membrane phospholipids by the 
enzyme PLA2, giving rise to signaling cascades that are known to lead to apoptosis evasion 
and tumor progression [312, 316]. Overall, both oxidative and signaling processes may 
contribute to the lower quantity of PUFA observed in membrane remodeling during cancer 
progression. 
Another process that is correlated with the oxidative stress and particularly the reactivity 
of the free radicals is the geometrical cis-trans lipid isomerization [314, 317]. As observed 
in the membranes of our animal models of study, the trans fatty acid levels changed 
significantly in the 5-week old tumor-bearing mice and this could be related to an increased 
radical -induced fatty acid isomerization. On the contrary, at the early (4-weeks) and late 
(17-weeks) tumor stages, a lesser isomerizing effect was detected (Table 4.3 and Figure 
4.3b). Indeed, the involvement of trans fatty acids (TFA) in cancer is still controversial 
[318] and no conclusive explanation can be given to this point for the pattern observed. 
The similarities found between tumor-bearing SCID and healthy Swiss mice cannot be 
currently explained, and further investigation has to be carried out for the elucidation of 
this observation. 
 
Table 4.4. Relative percentages (% rel) of fatty acids methyl esters (FAME) from red blood cell 
(RBC) membrane of tumor-bearing mice at different age points (4 weeks, 5 weeks and 17 weeks). 
P value represents the comparison among all the groups after conducting one-way ANOVA test in 
parallel with multiple comparisons of all groups (n=3). 
FAME 
Tumor 
SCID-4w 
Tumor 
SCID-5w 
Tumor  
SCID-17w 
p-value 
SFA 
14:0 0.31 ± 0.02 0.33 ± 0.02 0.54 ± 0.05 0.0103 
15:0 0.36 ± 0.05 0.46 ± 0.06 0.09 ± 0.07 0.0142 
16:0 28.61 ± 0.07 29.23 ± 0.91 38.52 ± 1.90 0.0053 
17:0 0.33 ± 0.01 0.45 ± 0.01 0.32 ± 0.04 0.0357 
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FAME 
Tumor 
SCID-4w 
Tumor 
SCID-5w 
Tumor  
SCID-17w 
p-value 
18:0 12.56 ± 0.06 12.08 ± 0.23 18.39 ± 2.02 0.0267 
MUFA 
16:1c6 0.26 ± 0.01 0.37 ± 0.08 0.22 ± 0.07 0.2394 
16:1c9 1.47 ± 0.21 1.37 ± 0.05 1.15 ± 0.65 0.8269 
18:1c9 16.05 ± 0.06 15.41 ± 0.53 12.10 ± 2.75 0.2525 
18:1c11 1.94 ± 0.08 1.99 ± 0.12 1.81 ± 0.11 0.4285 
20:1c11 0.37 ± 0.01 0.40 ± 0.01 0.24 ± 0.03 0.0089 
PUFA ω6 
18:2 10.97 ± 0.12 11.61 ± 0.07 9.67 ± 2.05 0.5189 
18:3 0.18 ± 0.01 0.09 ± 0.09 0.02 ± 0.03 0.1602 
20:2 0.35 ± 0.03 0.33 ± 0.02 0.35 ± 0.15 0.9857 
20:3 1.26 ± 0.10 1.26 ± 0.01 0.80 ± 0.08 0.0088 
20:4 15.81 ± 0.04 14.20 ± 0.09 10.07 ± 2.01 0.0463 
PUFA ω3 
18:3 0.19 ± 0.03 0.26 ± 0.07 0.17 ± 0.04 0.3714 
20:5 0.52 ± 0.03 0.53 ± 0.04 0.32 ± 0.07 0.0443 
22:5 0.76 ± 0.06 0.72 ± 0.05 0.87 ± 0.18 0.5865 
22:6 7.07 ± 0.03 7.60 ± 0.01 4.04 ± 0.74 0.0064 
trans 
18:1 0.20 ± 0.03 0.24 ± 0.07 0.03 ± 0.04 0.0379 
18:2 0.28 ± 0.01 0.44 ± 0.09 0.14 ± 0.05 0.0437 
20:4 0.07 ± 0.07 0.68 ± 0.15 0.15 ± 0.05 0.0134 
 
 
4.2.3 Tumor-bearing SCID mice treated with iron nanoparticles and bleomycin 
Previous research activity of CNR/Lipinutragen group has revealed the effects of 
bleomycin on the membrane lipidome of the neuroectodermal NTera2 tumor cell line and 
on biomimetic models (liposomes) [199, 200]. Our aim was to transfer the above studies 
to our in vivo model, which is a SCID mouse xenografted with the human glioblastoma 
U87MG cell line. In particular, 4-weeks old tumor-bearing SCID mice were randomly 
divided into four groups; Group 1 (control group) received normal saline, Group 2 received 
3 mg/kg (0.6 mg/mL) Fe3O4 metallo-nanoparticles (Fe-NPs) suspended in saline, Group 3 
received 15 mg/kg (3mg/mL) bleomycin and lastly, Group 4 received Fe-NPs plus 
bleomycin (co-treatment at the same concentrations as for groups 3 and 4). All 
administrations were performed intravenously. Animals were sacrificed 24 h after drug 
administration, red blood cells were isolated from whole blood and analyzed for assessing 
the membrane fatty acid composition, as depicted in Figure 4.4.  
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Figure 4.4: Protocol outline for the analysis and quantification of membrane fatty acid moieties in 
erythrocytes of tumor-bearing SCID mice after treatment with iron nanoparticles (NPs), bleomycin 
or combination of the them. 
 
Tumor-bearing SCID mice that underwent any treatment (Fe-NPs, Bleomycin, Fe-
NPs/Bleomycin) were characterized by an erythrocyte membrane lipidomic profile similar 
to untreated tumor-bearing SCID mice. The only significant difference observed was in the 
case of tumor-bearing SCID mice treated with the combination Fe-NPs/bleomycin, during 
which the ω-6/ω-3 ratio in RBC membrane was lower (p<0.05) compared to all other 
groups (Figure 4.5, Table 4.5). As far as the bleomycin is concerned, its administration 
(either alone or combined with Fe-NPs) did not provoke any alterations on erythrocytes 
membrane fatty acid composition. 
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Figure 4.5: (A) Relative (%) distribution of fatty acid families in erythrocyte membranes of 4-
weeks old tumor-bearing SCID mice treated with 3 mg/kg iron nanoparticles (Fe), 15 mg/kg 
bleomycin (Bleo) and the combination of them (Fe/Bleo) at the same concentrations. (B) 
Distribution of ω6 and ω3 polyunsaturated fatty acids and their ratio in erythrocyte membranes of 
4-weeks old tumor-bearing SCID mice treated with Fe-NPs/Bleomycin. Fatty acid analysis was 
performed 1-day post-treatment. Values represent Mean ± SD (n=3). SFA, saturated fatty acids; 
MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. Statistical significance 
was tested with the unpaired t-test. 
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Table 4.5: Erythrocyte membrane fatty acid composition of tumor-bearing SCID mice (4 weeks 
old) treated with Fe nanoparticles [3 mg/kg], bleomycin [15 mg/kg] and the combination of them 
at the same concentrations. The variance of each fatty acid among the different groups was studied 
with the ANOVA test. Multiple comparison test was applied to compare the differences among the 
distinct groups (* control vs x-treated, * Fe-NPs vs bleomycin, * Fe-NPs vs Fe-NPs/bleomycin, * 
Bleomycin vs Fe-NPs/bleomycin). 
FAME 
(% rel) 
Control Fe-NPs Bleomycin 
Fe-NPs/ 
Bleomycin 
ANOVA 
(p-value) 
SFA 42.16 ± 0.03 42.45 ± 1.78 43.10 ± 2.78 41.64 ± 0.21 0.8689 
MUFA 20.08 ± 0.08 18.51 ± 1.43 16.79 ± 1.49 19.26 ± 0.91 0.1572 
SFA/MUFA 2.10 ± 0.01 2.30 ± 0.18 2.60 ± 0.37 2.17 ± 0.11 0.2487 
PUFA 37.09 ± 0.13 37.28 ± 3.34 38.70 ± 1.86 38.18 ± 0.40 0.8649 
PUFA ω6 28.56 ± 0.04 28.62 ± 2.58 29.78 ± 1.53 28.33 ± 0.33 0.8122 
PUFA ω3 8.54 ± 0.09 8.67 ± 0.79 8.92 ± 0.49 9.84 ± 0.13 0.1379 
ω6/ω3 3.35 ± 0.03 3.30 ± 0.09 3.34 ± 0.16 2.88 ± 0.04*/*/* 0.0080 
total trans 0.55 ± 0.11 1.75 ± 0.86 1.41 ± 0.39 0.93 ± 0.54 0.3283 
UI 158.52 ± 0.43 156.32 ± 15.02 162.46 ± 8.60 166.56 ± 0.48 0.7199 
PI 141.79 ± 0.53 140.90 ± 17.63 149.31 ± 8.40 153.93 ± 1.14 0.6012 
 
 
4.2.4 Healthy Swiss mice treated with iron nanoparticles and bleomycin 
In parallel, the above-mentioned treatments were performed under the same conditions in 
healthy Swiss mice. Again, 4-weeks old Swiss mice were randomly divided into four 
groups; Group 1 (control group) received normal saline, Group 2 received 3 mg/kg (0.6 
mg/mL) Fe3O4 metallo-nanoparticles (Fe-NPs) suspended in saline, Group 3 received 15 
mg/kg (3mg/mL) bleomycin and lastly, Group 4 received Fe-NPs plus bleomycin (co-
treatment at the same concentrations as for groups 3 and 4). All administrations were 
performed intravenously. Animals were sacrificed 24 h after drug administration, red blood 
cells were isolated from whole blood and analyzed for assessing the membrane fatty acid 
composition, as depicted in Figure 4.6.  
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Figure 4.6: Protocol outline for the analysis and quantification of membrane fatty acid moieties in 
erythrocytes of healthy Swiss mice after treatment with iron nanoparticles (NPs), bleomycin or 
combination of the them. 
 
Healthy Swiss mice treated with Fe nanoparticles were characterized by a significantly 
different membrane lipidomic profile, compared to untreated or any other treated group, as 
shown in Figure 4.7A-C. In comparison to control Swiss mice, the Fe-NPs treated group 
showed lower SFA (p < 0.01) and PUFA (p < 0.001) content, whereas the MUFA members 
were increased (p < 0.001) 24 h after iron nanoparticles administration. Regarding the 
PUFA, both ω-6 and ω-3 family members were significantly decreased (p < 0.01 and 
p < 0.001, respectively). However, Swiss mice that were treated with Fe-NPs showed 
higher ω-6/ω-3 ratio with respect to untreated ones (p < 0.05), thus indicating an extended 
consumption of PUFA-ω3 members compared to the ω6 (Figure 4.7D). Consequently, the 
observed membrane remodeling led to the diminution of both unsaturation (UI) and 
peroxidation (PI) indices (p < 0.01 and p < 0.001, respectively).  
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Figure 4.7: (A-C) Relative (%) distribution of fatty acid families (SFA, MUFA and PUFA) in 
erythrocyte membranes of 4-weeks old normal Swiss mice treated with 3 mg/kg iron nanoparticles 
(Fe), 15 mg/kg bleomycin (Bleo) and the combination of them (Fe/Bleo) at the same concentrations. 
(D) Distribution of ω6 and ω3 polyunsaturated fatty acids and their ratio in erythrocyte membranes 
of 4-weeks normal Swiss mice treated with Fe-NPs. Fatty acid analysis was performed 1-day post-
treatment. Values represent Mean ± SD (n=3). SFA, saturated fatty acids; MUFA, monounsaturated 
fatty acids; PUFA, polyunsaturated fatty acids. Statistical significance was tested with the unpaired 
t-test. * (p< 0.05), ** (p< 0.01), *** (p< 0.001). 
 
Iron mediates the formation of reactive oxygen species (ROS) through the catalytic 
decomposition of hydrogen peroxide (Fenton reaction), which in turn lead to the damage 
of biomolecules, including lipids, proteins and DNA [293]. Oxidative damages to cellular 
components play a key role in tumor initiation and propagation. Studies on experimental 
animals have indicated that excess of iron accumulation in the liver and kidney causes 
oxidative tissue damages and is associated with cancer development in the respective organ 
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[319-322]. Interestingly, when Fe-NPs were administered simultaneously with bleomycin 
there was no alteration of membrane fatty acid composition, as compared to untreated mice 
(Table 4.6). The quenching of Fe-NPs effect on membrane lipidome could be probably due 
to the coordination of iron with bleomycin, since the latter acts as an iron chelator [323, 
324]. Consequently, this binding maybe blocks iron’s ability to catalyze the formation of 
free radicals. 
Although recent studies have shown that the bleomycin-iron complex can also interact with 
the membrane lipids due to its lipophilic characteristics [199, 200], we did not observe any 
similar effect on our in vivo models. More specifically, bleomycin has been found to induce 
in vitro a profound membrane remodeling at the level of the fatty acid constituents, which 
includes an increase of saturated fatty acid (SFA) content with a parallel decrease of 
monounsaturated and polyunsaturated fatty acids (MUFA and PUFA) [199]. Furthermore, 
studies on liposomes made of SFA, MUFA and PUFA-containing phospholipids have 
shown the occurrence of lipid isomerization, as well as the PUFA consumption, under 
biomimetic conditions of free radical and oxidative stress. In the present case, neither 
healthy Swiss mice, nor tumor-bearing SCID mice were characterized by such an 
eryhtrocyte membrane remodeling 24 h after bleomycin administration (Tables 4.5 and 
4.6).  
 
Table 4.6: Erythrocyte membrane fatty acid composition of healthy Swiss mice (4-weeks old) 
treated with Fe nanoparticles (3 mg/kg), bleomycin (15 mg/kg) and the combination of them at the 
same concentrations. The variance of each fatty acid among the different groups was studied with 
the ANOVA test. Multiple comparison test was applied to compare the differences among the 
distinct groups (* control vs x-treated, * Fe-NPs vs bleomycin, * Fe-NPs vs Fe-NPs/bleomycin, * 
Bleomycin vs Fe-NPs/bleomycin). 
FAME 
(% rel) 
Control Fe-NPs Bleomycin 
Fe-NPs/ 
Bleomycin 
ANOVA 
(p-value) 
SFA 42.91 ± 1.41 36.74 ± 1.98** 40.50 ± 0.45 41.85 ± 0.25* 0.0053 
MUFA 20.63 ± 1.49 33.56 ± 2.36*** 22.41 ± 0.65*** 21.63 ± 1.27*** 0.0001 
SFA/MUFA 2.10 ± 0.22 1.10 ± 0.13*** 1.81 ± 0.07** 1.94 ± 0.11** 0.0005 
PUFA 35.42 ± 1.15 29.08 ± 0.38*** 36.09 ± 0.77*** 35.60 ± 1.33*** 0.0003 
PUFA ω6 27.26 ± 0.97 23.34 ± 0.12** 28.08 ± 0.60** 27.52 ± 1.23** 0.0018 
PUFA ω3 8.17 ± 0.21 5.74 ± 0.44*** 8.02 ± 0.20*** 8.08 ± 0.37*** 0.0002 
ω6/ω3 3.34 ± 0.07 4.09 ± 0.35* 3.50 ± 0.05 3.41 ± 0.21* 0.0225 
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FAME 
(% rel) 
Control Fe-NPs Bleomycin 
Fe-NPs/ 
Bleomycin 
ANOVA 
(p-value) 
Total trans 1.04 ± 0.74 0.62 ± 0.19 0.99 ± 0.40 0.93 ± 0.20 0.7776 
UI 151.42 ± 5.36 128.14 ± 3.09** 153.24 ± 2.85** 152.38 ± 4.14** 0.0006 
PI 133.03 ± 5.69 90.01 ± 7.64*** 131.81 ± 3.85*** 132.77 ± 5.31*** 0.0002 
 
Apart from the lipid peroxidation process, ROS production can induce the interconversion 
of the cis unsaturated fatty acids to their corresponding trans geometrical isomers. This 
process is catalyzed by thiyl radicals, which are generated endogenously under stress 
conditions [317, 325]. In this study, we did not observe significant changes on trans 
isomers. The total content of trans FA in healthy Swiss mice treated with Fe-NPs was 
decreased, not significantly though. These preliminary observations also suggest a different 
effect of iron nanoparticles on erythrocyte fatty acids composition between healthy and 
tumor-bearing mice. However, further investigation is needed to better evaluate the 
obtained results. 
 
 
4.3 Conclusions 
In the present research project, we monitored the fatty acid composition of erythrocyte 
membrane phospholipids during tumor development. The membrane lipidomic profiles 
were analyzed in tumor-bearing SCID mice, xenografted with the human glioblastoma 
U87MG cell line, at early and late stages of tumor progression. Regarding the membrane 
fatty acid remodeling, late stage, and early stage tumor-bearing mice showed significant 
differences. Specifically, they were characterized by statistically significant increase of 
SFA, accompanied by a decrease in PUFA (both ω-6 and ω-3 counterparts), unsaturation 
index (UI) and peroxidation index (PI) at late tumor progression. In parallel, we also 
studied the effect of iron nanoparticles and bleomycin administration at early stage of tumor 
occurrence in the same animal model, as well as in healthy Swiss mice. Bleomycin did no 
exert any significant effect on erythrocyte membrane lipidomic profile of either the tumor-
bearing or the healthy mice. Co-treatment of tumor diseased mice with Fe-NPs and 
bleomycin led to lower ω-6/ω-3 ratio in erythrocyte membrane. Iron nanoparticles caused 
a notable membrane remodeling in healthy Swiss mice, characterized by lower SFA and 
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PUFA levels and higher MUFA content. Although both ω-6 and ω-3 PUFA families were 
decreased, their ratio (ω-6/ω-3) was found increased in Fe-NPs treated Swiss mice, 
compared to the untreated group. In this study, the erythrocytes were used as ‘reporter cells’ 
to evaluate the fatty acid composition of tumor-bearing mice, since they can be indicative 
of the membrane exposure to the redox status. The effect of high oxidative stress can be 
depicted through the PUFA consumption and the consequent membrane remodeling. As a 
result, fatty acid-based membrane lipidomics could be a valuable tool, which allows the 
follow-up of fatty acid alterations and contribute to the development of multi-targeted 
antitumoral approaches.  
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7. Abbreviations 
ACC Acetyl-CoA carboxylase 
ACLY Adenosine triphosphate (ATP) citrate lyase 
ALA α-linolenic acid 
ARA Arachidonic acid 
CAT Catalase 
Co-A Coenzyme A 
Cu-TPMA-Phen [Cu(TPMA)(Phen)](ClO4)2, TPMA = tris-(2-pyridylmethyl)amine, 
Phen = 1,10-phenanthroline 
DAG Diacylglycerol 
DHA Docosahexaenoic acid 
DGLA Dihomo-gamma-linolenic acid 
DPA Docosapentaenoic acid 
EC50 Half-maximal effective concentration 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol tetraacetic acid 
EPA Eicosapentaenoic acid 
ER Endoplasmic reticulum 
FA Fatty acids 
FAME Fatty acid methyl esters 
FADS Fatty acid desaturase 
FASN Fatty acid synthase 
Fe-NPs Iron nanoparticles 
GC Gas chromatography 
GLA γ-linolenic acid 
GPL Glycerophospholipids 
HDFM Hyperspectral dark field microscopy 
LA Linoleic acid 
MCF7 Michigan Cancer Foundation-7, breast cancer cell line 
MTBE Methyl tert-butyl ether 
MUFA Monounsaturated fatty acids 
NAC N-acetyl-cysteine 
NADH Nicotinamide adenine dinucleotide 
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NADPH Nicotinamide adenine dinucleotide phosphate 
NB100 Neuroblastoma-derived cell line 
NCs Nanocontainers 
NEC-1 Necrostatin-1 
PBS Phosphate buffered saline 
PC Phosphatidylcholine 
PE Phosphatidylethanolamine 
PI Peroxidation index 
PLA2 Phospholipase A2 
PS Phosphatidylserine 
PUFA Polyunsaturated fatty acids 
RBC Red blood cell 
ROS Reactive oxygen species 
SCD Stearoyl-CoA-desaturase 
SCID Severe combined immunodeficiency 
SFA Saturated fatty acids 
SM Sphingomyelin 
SPL Sphingophospholipids 
SREBP Sterol regulatory element-binding protein 
TG Triglycerides 
TMSH Trimethylsulfonium hydroxide solution 
TFA Trans fatty acids 
U87MG Uppsala 87 Malignant Glioma 
UFA Unsaturated fatty acids 
UI Unsaturation index 
VLCFA Very long chain fatty acids 
Z-VAD N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone 
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